{"ID": "DDI-DrugBank.d481.s0.p0", "TEXT1": "It is possible that milk, milk products, and @DRUG$-rich foods or drugs could impair the absorption of @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["calcium", "drug", "25-31"], "DRUGB": ["EMCYT", "brand", "82-86"]}
{"ID": "DDI-DrugBank.d419.s0.p0", "TEXT1": "The concurrent administration of @DRUG$ and @DRUG$ is reported to substantially increase the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "LBL": "DDI-effect", "DRUGA": ["allopurinol", "drug", "33-43"], "DRUGB": ["ampicillin", "drug", "49-58"]}
{"ID": "DDI-DrugBank.d419.s0.p1", "TEXT1": "Using @DRUG$ and ampicillin together may cause a higher incidence of rashes in patients than if they were taking @DRUG$ alone.", "LBL": "0", "DRUGA": ["allopurinol", "drug", "33-43"], "DRUGB": ["ampicillin", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d419.s0.p2", "TEXT1": "The administration of allopurinol and @DRUG$ concurrently may increase the incidence of rashes in patients receiving both drugs, as compared to patients receiving @DRUG$ alone.", "LBL": "0", "DRUGA": ["ampicillin", "drug", "49-58"], "DRUGB": ["ampicillin", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d419.s1.p0", "TEXT1": "Description: It is not known for certain whether this potentiation of @DRUG$ rashes is due to @DRUG$ or the hyperuricemia present in these patients. However, further research may help shed light on this interaction.", "LBL": "DDI-effect", "DRUGA": ["ampicillin", "drug", "45-54"], "DRUGB": ["allopurinol", "drug", "73-83"]}
{"ID": "DDI-DrugBank.d419.s2.p0", "TEXT1": "In clinical trials of @DRUG$, 22 patients received both @DRUG$ and AUGMENTIN XR.", "LBL": "0", "DRUGA": ["AUGMENTIN XR", "brand", "33-44"], "DRUGB": ["allopurinol", "drug", "80-90"]}
{"ID": "DDI-DrugBank.d419.s2.p1", "TEXT1": "In clinical trials of @DRUG$, 22 patients received concomitant allopurinol and @DRUG$. There were no reports of any adverse effects from this combination therapy.", "LBL": "0", "DRUGA": ["AUGMENTIN XR", "brand", "33-44"], "DRUGB": ["AUGMENTIN XR", "brand", "96-107"]}
{"ID": "DDI-DrugBank.d419.s2.p2", "TEXT1": "In clinical trials of AUGMENTIN XR, 22 patients who received concomitant @DRUG$ and @DRUG$ experienced no adverse effects.", "LBL": "0", "DRUGA": ["allopurinol", "drug", "80-90"], "DRUGB": ["AUGMENTIN XR", "brand", "96-107"]}
{"ID": "DDI-DrugBank.d419.s4.p0", "TEXT1": "Although the sample size is small, it does not allow for any conclusions to be drawn regarding the risk of rashes with using @DRUG$ and @DRUG$ together.", "LBL": "0", "DRUGA": ["AUGMENTIN XR", "brand", "126-137"], "DRUGB": ["allopurinol", "drug", "143-153"]}
{"ID": "DDI-DrugBank.d419.s5.p0", "TEXT1": "The efficacy of oral contraceptives may be reduced when taken with @DRUG$, as is the case with other @DRUG$.", "LBL": "0", "DRUGA": ["broad-spectrum antibiotics", "group", "21-46"], "DRUGB": ["AUGMENTIN XR", "brand", "49-60"]}
{"ID": "DDI-DrugBank.d419.s5.p1", "TEXT1": "As with other @DRUG$, there is a possibility that AUGMENTIN XR may reduce the efficacy of oral @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["broad-spectrum antibiotics", "group", "21-46"], "DRUGB": ["contraceptives", "group", "94-107"]}
{"ID": "DDI-DrugBank.d419.s5.p2", "TEXT1": "In common with other broad-spectrum antibiotics, @DRUG$ may reduce the efficacy of oral contraceptive pills.", "LBL": "DDI-effect", "DRUGA": ["AUGMENTIN XR", "brand", "49-60"], "DRUGB": ["contraceptives", "group", "94-107"]}
{"ID": "DDI-DrugBank.d234.s0.p0", "TEXT1": "Different @DRUG$ may interact with each other in different ways; with regard to @DRUG$, however, no specific interactions have been studied.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "17-50"], "DRUGB": ["benzodiazepines", "group", "63-77"]}
{"ID": "DDI-DrugBank.d234.s1.p0", "TEXT1": "There were no deleterious interactions seen when @DRUG$ was administered after @DRUG$, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "52-60"], "DRUGB": ["narcotics", "group", "85-93"]}
{"ID": "DDI-DrugBank.d234.s1.p1", "TEXT1": "There were no deleterious interactions seen when @DRUG$ was administered after narcotics, inhalational @DRUG$, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "52-60"], "DRUGB": ["anesthetics", "group", "109-119"]}
{"ID": "DDI-DrugBank.d234.s1.p2", "TEXT1": "There were no deleterious interactions seen when @DRUG$ was administered after narcotics, inhalational anesthetics, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "52-60"], "DRUGB": ["muscle relaxants", "group", "122-137"]}
{"ID": "DDI-DrugBank.d234.s1.p3", "TEXT1": "There were no deleterious interactions seen when ROMAZICON was administered after @DRUG$, inhalational @DRUG$, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["narcotics", "group", "85-93"], "DRUGB": ["anesthetics", "group", "109-119"]}
{"ID": "DDI-DrugBank.d234.s1.p4", "TEXT1": "No deleterious interactions were seen when ROMAZICON was administered after @DRUG$, inhalational anesthetics, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["narcotics", "group", "85-93"], "DRUGB": ["muscle relaxants", "group", "122-137"]}
{"ID": "DDI-DrugBank.d234.s1.p5", "TEXT1": "There were no harmful interactions noted when ROMAZICON was given after narcotics, inhalational @DRUG$, @DRUG$ and muscle relaxant antagonists were given along with sedation or anesthesia.", "LBL": "0", "DRUGA": ["anesthetics", "group", "109-119"], "DRUGB": ["muscle relaxants", "group", "122-137"]}
{"ID": "DDI-DrugBank.d234.s2.p0", "TEXT1": "Particular care is needed when using @DRUG$ in cases of mixed drug overdose, as the toxic effects (such asconvulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may become apparent when the benzodiazepine effect is reversed by flumazenil.", "LBL": "DDI-effect", "DRUGA": ["ROMAZICON", "brand", "43-51"], "DRUGB": ["cyclic antidepressants", "group", "203-224"]}
{"ID": "DDI-DrugBank.d234.s2.p1", "TEXT1": "Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage. The toxic effects of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the @DRUG$ effect by flumazenil.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "43-51"], "DRUGB": ["benzodiazepine", "group", "263-276"]}
{"ID": "DDI-DrugBank.d234.s2.p2", "TEXT1": "It is important to be careful when using @DRUG$ in cases of mixed drug overdose, as the toxic effects of other drugs taken in overdose (especially cyclic antidepressants) may become apparent when the benzodiazepine effect is reversed by @DRUG$.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "43-51"], "DRUGB": ["flumazenil", "drug", "288-297"]}
{"ID": "DDI-DrugBank.d234.s2.p3", "TEXT1": "Particular care is needed when using ROMAZICON in cases of mixed drug overdose, as the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge when the effect of @DRUG$ is reversed by flumazenil.", "LBL": "0", "DRUGA": ["cyclic antidepressants", "group", "203-224"], "DRUGB": ["benzodiazepine", "group", "263-276"]}
{"ID": "DDI-DrugBank.d234.s2.p4", "TEXT1": "We advise extra vigilance when using ROMAZICON to treat cases of drug overdose, as the reversal of benzodiazepine effect by @DRUG$ may cause other drugs taken in overdose (such as @DRUG$) to become more toxic.", "LBL": "0", "DRUGA": ["cyclic antidepressants", "group", "203-224"], "DRUGB": ["flumazenil", "drug", "288-297"]}
{"ID": "DDI-DrugBank.d234.s2.p5", "TEXT1": "Particular care is necessary when using ROMAZICON in cases of mixed drug overdosage, as the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge along with the reversal of the @DRUG$ effect by @DRUG$.", "LBL": "0", "DRUGA": ["benzodiazepine", "group", "263-276"], "DRUGB": ["flumazenil", "drug", "288-297"]}
{"ID": "DDI-DrugBank.d234.s4.p0", "TEXT1": "Although @DRUG$ has a small intrinsic effect of reducing seizures, its sudden removal of the protective effect of a @DRUG$ agonist can cause convulsions in epileptic patients.", "LBL": "DDI-effect", "DRUGA": ["ROMAZICON", "brand", "9-17"], "DRUGB": ["benzodiazepine", "group", "121-134"]}
{"ID": "DDI-DrugBank.d234.s5.p0", "TEXT1": "The concurrent use of @DRUG$ and @DRUG$ is not recommended, as @DRUG$ may reduce the efficacy of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["ROMAZICON", "brand", "0-8"], "DRUGB": ["benzodiazepines", "group", "40-54"]}
{"ID": "DDI-DrugBank.d234.s6.p0", "TEXT1": "The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as @DRUG$, triazolopyridazines and others, may be reduced when used with @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["zopiclone", "drug", "79-87"], "DRUGB": ["ROMAZICON", "brand", "142-150"]}
{"ID": "DDI-DrugBank.d234.s7.p0", "TEXT1": "The pharmacokinetics of @DRUG$ are not affected by the presence of @DRUG$, and vice versa.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "24-38"], "DRUGB": ["flumazenil", "drug", "73-82"]}
{"ID": "DDI-DrugBank.d234.s8.p0", "TEXT1": "There is no pharmacokinetic interaction between @DRUG$ and @DRUG$. Both drugs are metabolized by the liver and no significant interaction is expected.", "LBL": "0", "DRUGA": ["ethanol", "drug", "48-54"], "DRUGB": ["flumazenil", "drug", "60-69"]}
{"ID": "DDI-DrugBank.d234.s9.p0", "TEXT1": "Some people may find that the effects of @DRUG$ wear off before the @DRUG$ is completely cleared from the body.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "42-50"], "DRUGB": ["long-acting benzodiazepine", "group", "74-99"]}
{"ID": "DDI-DrugBank.d234.s11.p0", "TEXT1": "Any patient in whom either @DRUG$ (such as @DRUG$) or large doses of short-acting benzodiazepines (such as 10 mg of midazolam) have been used should be observed for an adequate period of time.", "LBL": "0", "DRUGA": ["long-acting benzodiazepines", "group", "82-108"], "DRUGB": ["diazepam", "drug", "119-126"]}
{"ID": "DDI-DrugBank.d234.s11.p1", "TEXT1": "It is important to provide adequate observation for any patient who has received either @DRUG$ (such as diazepam) or large doses of @DRUG$ (such as 10 mg of midazolam).", "LBL": "0", "DRUGA": ["long-acting benzodiazepines", "group", "82-108"], "DRUGB": ["short-acting benzodiazepines", "group", "147-174"]}
{"ID": "DDI-DrugBank.d234.s11.p2", "TEXT1": "Patients who have used @DRUG$ or large doses of short-acting benzodiazepines should be observed for an adequate period of time.", "LBL": "0", "DRUGA": ["long-acting benzodiazepines", "group", "82-108"], "DRUGB": ["midazolam", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d234.s11.p3", "TEXT1": "A period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as @DRUG$) or large doses of @DRUG$ (such as 10 mg of midazolam) have been used, in order to ensure their safety.", "LBL": "0", "DRUGA": ["diazepam", "drug", "119-126"], "DRUGB": ["short-acting benzodiazepines", "group", "147-174"]}
{"ID": "DDI-DrugBank.d234.s11.p4", "TEXT1": "A reasonable timeframe must be observed for any patient in whom either long-acting benzodiazepines (such as @DRUG$) or large doses of short-acting benzodiazepines (such as  10 mg of @DRUG$) have been used. This is to allows for full understanding of the potential effects.", "LBL": "0", "DRUGA": ["diazepam", "drug", "119-126"], "DRUGB": ["midazolam", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d234.s11.p5", "TEXT1": "It is important to provide adequate observation for any patient who has received either long-acting benzodiazepines (such as diazepam) or large doses of @DRUG$ (such as 10 mg of @DRUG$).", "LBL": "0", "DRUGA": ["short-acting benzodiazepines", "group", "147-174"], "DRUGB": ["midazolam", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d234.s12.p0", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "84-98"], "DRUGB": ["benzodiazepine", "group", "215-228"]}
{"ID": "DDI-DrugBank.d234.s12.p1", "TEXT1": "It is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned. This is because there is an increased risk of adverse reactions in patients who have been taking @DRUG$ regularly.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "84-98"], "DRUGB": ["alcohol", "drug", "231-237"]}
{"ID": "DDI-DrugBank.d234.s12.p2", "TEXT1": "It is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "84-98"], "DRUGB": ["sedative", "group", "243-250"]}
{"ID": "DDI-DrugBank.d234.s12.p3", "TEXT1": "Because some patients may be taking @DRUG$ on a regular basis, it is important for physicians to ask about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned. This will help to minimize the risk of adverse reaction", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "84-98"], "DRUGB": ["ROMAZICON", "brand", "322-330"]}
{"ID": "DDI-DrugBank.d234.s12.p4", "TEXT1": "Since patients who have been taking benzodiazepines regularly are at an increased risk of adverse reactions, it is especially important that physicians ask patients or their guardians about @DRUG$, @DRUG$ and sedative use before any procedure in which ROMAZICON is planned.", "LBL": "0", "DRUGA": ["benzodiazepine", "group", "215-228"], "DRUGB": ["alcohol", "drug", "231-237"]}
{"ID": "DDI-DrugBank.d234.s12.p5", "TEXT1": "Given that patients who have been taking benzodiazepines regularly are at an increased risk of adverse reactions, it is especially important that physicians ask patients or their guardians about @DRUG$, alcohol, and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "LBL": "0", "DRUGA": ["benzodiazepine", "group", "215-228"], "DRUGB": ["sedative", "group", "243-250"]}
{"ID": "DDI-DrugBank.d234.s12.p6", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is especially important that physicians query patients or their guardians carefully about @DRUG$, alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.", "LBL": "0", "DRUGA": ["benzodiazepine", "group", "215-228"], "DRUGB": ["ROMAZICON", "brand", "322-330"]}
{"ID": "DDI-DrugBank.d234.s12.p7", "TEXT1": "Benzodiazepines are associated with an increased risk of adverse reactions, so it is important that physicians query patients or their guardians about benzodiazepine, @DRUG$ and @DRUG$ use prior to any procedure in which the use of ROMAZICON is planned.", "LBL": "0", "DRUGA": ["alcohol", "drug", "231-237"], "DRUGB": ["sedative", "group", "243-250"]}
{"ID": "DDI-DrugBank.d234.s12.p8", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines regularly, it is very important that physicians carefully question patients or their guardians about benzodiazepine, @DRUG$ and sedative use as part of the history prior to any procedure where @DRUG$ is planned.", "LBL": "0", "DRUGA": ["alcohol", "drug", "231-237"], "DRUGB": ["ROMAZICON", "brand", "322-330"]}
{"ID": "DDI-DrugBank.d234.s12.p9", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of @DRUG$ is planned. This will help to ensure the safety of the patient during the procedure.", "LBL": "0", "DRUGA": ["sedative", "group", "243-250"], "DRUGB": ["ROMAZICON", "brand", "322-330"]}
{"ID": "DDI-DrugBank.d470.s1.p0", "TEXT1": "Coadministration of @DRUG$ with other medications that can prolong the QT interval (e.g. certain @DRUG$ or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B) is not advised.", "LBL": "DDI-advise", "DRUGA": ["TRISENOX", "brand", "24-31"], "DRUGB": ["antiarrhythmics", "group", "121-135"]}
{"ID": "DDI-DrugBank.d470.s1.p1", "TEXT1": "Use caution when @DRUG$ is coadministered with medications that can prolong the QT interval (e.g. certain antiarrhythmics or @DRUG$) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "LBL": "DDI-advise", "DRUGA": ["TRISENOX", "brand", "24-31"], "DRUGB": ["thioridazine", "drug", "140-151"]}
{"ID": "DDI-DrugBank.d470.s1.p2", "TEXT1": "Caution is advised when @DRUG$ is coadministered with other medications that can prolong the QT interval or lead to electrolyte abnormalities.", "LBL": "DDI-advise", "DRUGA": ["TRISENOX", "brand", "24-31"], "DRUGB": ["diuretics", "group", "200-208"]}
{"ID": "DDI-DrugBank.d470.s1.p3", "TEXT1": "Caution is advised when @DRUG$ is co-administered with other medications that could potentially prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or @DRUG$).", "LBL": "DDI-advise", "DRUGA": ["TRISENOX", "brand", "24-31"], "DRUGB": ["amphotericin B", "drug", "213-226"]}
{"ID": "DDI-DrugBank.d470.s1.p4", "TEXT1": "Please be cautious when taking TRISENOX along with other medications that can prolong the QT interval (e.g. certain @DRUG$ or @DRUG$) or that may lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "LBL": "0", "DRUGA": ["antiarrhythmics", "group", "121-135"], "DRUGB": ["thioridazine", "drug", "140-151"]}
{"ID": "DDI-DrugBank.d470.s1.p5", "TEXT1": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval or lead to electrolyte abnormalities.", "LBL": "0", "DRUGA": ["antiarrhythmics", "group", "121-135"], "DRUGB": ["diuretics", "group", "200-208"]}
{"ID": "DDI-DrugBank.d470.s1.p6", "TEXT1": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain @DRUG$ or thioridazine) or lead to electrolyte abnormalities (such as diuretics or @DRUG$).", "LBL": "0", "DRUGA": ["antiarrhythmics", "group", "121-135"], "DRUGB": ["amphotericin B", "drug", "213-226"]}
{"ID": "DDI-DrugBank.d470.s1.p7", "TEXT1": "Caution should be exercised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or @DRUG$) or lead to electrolyte abnormalities (such as @DRUG$ or amphotericin B).", "LBL": "0", "DRUGA": ["thioridazine", "drug", "140-151"], "DRUGB": ["diuretics", "group", "200-208"]}
{"ID": "DDI-DrugBank.d470.s1.p8", "TEXT1": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or @DRUG$) or lead to electrolyte abnormalities (such as diuretics or @DRUG$).", "LBL": "0", "DRUGA": ["thioridazine", "drug", "140-151"], "DRUGB": ["amphotericin B", "drug", "213-226"]}
{"ID": "DDI-DrugBank.d470.s1.p9", "TEXT1": "You should use caution when taking TRISENOX with other medications that can prolong the QT interval or lead to electrolyte abnormalities, such as @DRUG$ or @DRUG$.", "LBL": "0", "DRUGA": ["diuretics", "group", "200-208"], "DRUGB": ["amphotericin B", "drug", "213-226"]}
{"ID": "DDI-DrugBank.d278.s0.p0", "TEXT1": "The concomitant administration of @DRUG$ and @DRUG$ did not appear to alter the pharmacokinetics or level of platelet aggregation in healthy adults.", "LBL": "0", "DRUGA": ["Enoxaparin", "drug", "0-9"], "DRUGB": ["eptifibatide", "drug", "113-124"]}
{"ID": "DDI-DrugBank.d526.s1.p0", "TEXT1": "@DRUG$ and @DRUG$ enhance hypokalemia by promoting the loss of potassium in the body.", "LBL": "0", "DRUGA": ["Amphotericin B", "drug", "0-13"], "DRUGB": ["potassium-depleting diuretics", "group", "18-46"]}
{"ID": "DDI-DrugBank.d526.s1.p1", "TEXT1": "If @DRUG$ and potassium-depleting diuretics are used together, there is an increased risk of hypokalemia.", "LBL": "0", "DRUGA": ["Amphotericin B", "drug", "0-13"], "DRUGB": ["benzothiadiazines", "group", "49-65"]}
{"ID": "DDI-DrugBank.d526.s1.p2", "TEXT1": "@DRUG$ or potassium-depleting diuretics (benzothiadiazines and related drugs, @DRUG$ and furosemide) increased the risk of hypokalemia.", "LBL": "0", "DRUGA": ["Amphotericin B", "drug", "0-13"], "DRUGB": ["ethacrynic acid", "drug", "86-100"]}
{"ID": "DDI-DrugBank.d526.s1.p3", "TEXT1": "@DRUG$ may enhance the effects of potassium-depleting diuretics, which could lead to hypokalemia. Therefore, caution is advised when using these medications together.", "LBL": "0", "DRUGA": ["Amphotericin B", "drug", "0-13"], "DRUGB": ["furosemide", "drug", "106-115"]}
{"ID": "DDI-DrugBank.d526.s1.p4", "TEXT1": "Amphotericin B or @DRUG$ (@DRUG$ and related drugs, ethacrynic acid and furosemide) may enhance hypokalemia.", "LBL": "0", "DRUGA": ["potassium-depleting diuretics", "group", "18-46"], "DRUGB": ["benzothiadiazines", "group", "49-65"]}
{"ID": "DDI-DrugBank.d526.s1.p5", "TEXT1": "Amphotericin B or @DRUG$ (benzothiadiazines and related drugs, @DRUG$ and furosemide) increased the risk of hypokalemia.", "LBL": "0", "DRUGA": ["potassium-depleting diuretics", "group", "18-46"], "DRUGB": ["ethacrynic acid", "drug", "86-100"]}
{"ID": "DDI-DrugBank.d526.s1.p6", "TEXT1": "Amphotericin B or @DRUG$ (benzothiadiazines and related drugs, ethacrynic acid and @DRUG$) may increase the risk of hypokalemia.", "LBL": "0", "DRUGA": ["potassium-depleting diuretics", "group", "18-46"], "DRUGB": ["furosemide", "drug", "106-115"]}
{"ID": "DDI-DrugBank.d526.s1.p7", "TEXT1": "Amphotericin B or potassium-depleting diuretics (@DRUG$ and related drugs, @DRUG$ and furosemide) increased the risk of hypokalemia.", "LBL": "0", "DRUGA": ["benzothiadiazines", "group", "49-65"], "DRUGB": ["ethacrynic acid", "drug", "86-100"]}
{"ID": "DDI-DrugBank.d526.s1.p8", "TEXT1": "Amphotericin B or potassium-depleting diuretics (@DRUG$ and related drugs, ethacrynic acid and @DRUG$) increased the risk of hypokalemia.", "LBL": "0", "DRUGA": ["benzothiadiazines", "group", "49-65"], "DRUGB": ["furosemide", "drug", "106-115"]}
{"ID": "DDI-DrugBank.d526.s1.p9", "TEXT1": "Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, @DRUG$ and @DRUG$) can increase the risk of hypokalemia.", "LBL": "0", "DRUGA": ["ethacrynic acid", "drug", "86-100"], "DRUGB": ["furosemide", "drug", "106-115"]}
{"ID": "DDI-DrugBank.d526.s4.p0", "TEXT1": "There is an enhanced possibility of arrhythmias or @DRUG$ toxicity associated with hypokalemia when taking @DRUG$.", "LBL": "0", "DRUGA": ["Digitalis glycosides", "group", "0-19"], "DRUGB": ["digitalis", "group", "60-68"]}
{"ID": "DDI-DrugBank.d526.s9.p0", "TEXT1": "The oral agents @DRUG$ and @DRUG$ may reduce the antidiabetic effect.", "LBL": "0", "DRUGA": ["Antidiabetic drugs", "group", "0-17"], "DRUGB": ["insulin", "drug", "36-42"]}
{"ID": "DDI-DrugBank.d526.s14.p0", "TEXT1": "There is a rare possibility that @DRUG$ toxicity may occur in patients who discontinue @DRUG$ after concurrent high-dose aspirin therapy.", "LBL": "0", "DRUGA": ["salicylate", "group", "7-16"], "DRUGB": ["steroids", "group", "65-72"]}
{"ID": "DDI-DrugBank.d526.s14.p1", "TEXT1": "Rarely, patients who discontinue steroids after concurrent high-dose @DRUG$ therapy may experience @DRUG$ toxicity.", "LBL": "0", "DRUGA": ["salicylate", "group", "7-16"], "DRUGB": ["aspirin", "brand", "101-107"]}
{"ID": "DDI-DrugBank.d526.s14.p2", "TEXT1": "In rare cases, patients who discontinue @DRUG$ after concurrent high-dose @DRUG$ therapy may experience salicylate toxicity.", "LBL": "DDI-effect", "DRUGA": ["steroids", "group", "65-72"], "DRUGB": ["aspirin", "brand", "101-107"]}
{"ID": "DDI-DrugBank.d526.s15.p0", "TEXT1": "Monitor @DRUG$ levels or the therapeutic effect for which @DRUG$ is given; this will help ensure that the drug is effective.", "LBL": "0", "DRUGA": ["salicylate", "group", "8-17"], "DRUGB": ["aspirin", "brand", "62-68"]}
{"ID": "DDI-DrugBank.d526.s17.p0", "TEXT1": "Fludrocortisone acetate's metabolic clearance is increased by @DRUG$, @DRUG$, or rifampin because these drugs induce hepatic enzymes.", "LBL": "0", "DRUGA": ["Barbiturates", "group", "0-11"], "DRUGB": ["phenytoin", "drug", "14-22"]}
{"ID": "DDI-DrugBank.d526.s17.p1", "TEXT1": "If @DRUG$, phenytoin, or @DRUG$ are used together with fludrocortisone acetate, it is recommended to exercise caution because these drugs can increase the metabolic clearance of fludrocortisone acetate.", "LBL": "0", "DRUGA": ["Barbiturates", "group", "0-11"], "DRUGB": ["rifampin", "drug", "28-35"]}
{"ID": "DDI-DrugBank.d526.s17.p2", "TEXT1": "@DRUG$ may have an increased metabolism due to induction of hepatic enzymes when given with phenytoin or rifampin.", "LBL": "DDI-mechanism", "DRUGA": ["Barbiturates", "group", "0-11"], "DRUGB": ["fludrocortisone acetate", "drug", "70-92"]}
{"ID": "DDI-DrugBank.d526.s17.p3", "TEXT1": "Barbiturates, @DRUG$, or @DRUG$ increased the metabolic clearance of fludrocortisone acetate because they induced hepatic enzymes.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "14-22"], "DRUGB": ["rifampin", "drug", "28-35"]}
{"ID": "DDI-DrugBank.d526.s17.p4", "TEXT1": "Barbiturates, @DRUG$, or rifampin increased metabolic clearance of @DRUG$ because they stimulated hepatic enzymes.", "LBL": "DDI-mechanism", "DRUGA": ["phenytoin", "drug", "14-22"], "DRUGB": ["fludrocortisone acetate", "drug", "70-92"]}
{"ID": "DDI-DrugBank.d526.s17.p5", "TEXT1": "Taking barbiturates, phenytoin, or @DRUG$ may increase the metabolic clearance of @DRUG$ because of the induction of hepatic enzymes.", "LBL": "DDI-mechanism", "DRUGA": ["rifampin", "drug", "28-35"], "DRUGB": ["fludrocortisone acetate", "drug", "70-92"]}
{"ID": "DDI-DrugBank.d526.s18.p0", "TEXT1": "Monitor the patient for possible diminished effect of @DRUG$ and increase the @DRUG$ dosage as needed.", "LBL": "0", "DRUGA": ["steroid", "group", "54-60"], "DRUGB": ["steroid", "group", "79-85"]}
{"ID": "DDI-DrugBank.d526.s19.p0", "TEXT1": "The use of @DRUG$ in conjunction with C-17 alkylated compounds such as oxymetholone, methandrostenolone, and norethandrolone may increase the risk of edema.", "LBL": "0", "DRUGA": ["Anabolic steroids", "group", "0-16"], "DRUGB": ["androgens", "group", "47-55"]}
{"ID": "DDI-DrugBank.d526.s19.p1", "TEXT1": "@DRUG$ (particularly C-17 alkylated androgens such as @DRUG$, methandrostenolone, norethandrolone, and similar compounds) increased the risk of edema.", "LBL": "0", "DRUGA": ["Anabolic steroids", "group", "0-16"], "DRUGB": ["oxymetholone", "drug", "65-76"]}
{"ID": "DDI-DrugBank.d526.s19.p2", "TEXT1": "@DRUG$, particularly C-17 alkylated androgens such as oxymetholone, @DRUG$, norethandrolone, and similar compounds, may make edema more likely.", "LBL": "0", "DRUGA": ["Anabolic steroids", "group", "0-16"], "DRUGB": ["methandrostenolone", "drug", "79-96"]}
{"ID": "DDI-DrugBank.d526.s19.p3", "TEXT1": "Compounds in @DRUG$ (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, @DRUG$, and similar compounds) have been shown to enhance the tendency toward edema.", "LBL": "0", "DRUGA": ["Anabolic steroids", "group", "0-16"], "DRUGB": ["norethandrolone", "drug", "99-113"]}
{"ID": "DDI-DrugBank.d526.s19.p4", "TEXT1": "Anabolic steroids may increase the risk of edema when used in combination with @DRUG$.", "LBL": "0", "DRUGA": ["androgens", "group", "47-55"], "DRUGB": ["oxymetholone", "drug", "65-76"]}
{"ID": "DDI-DrugBank.d526.s19.p5", "TEXT1": "Anabolic steroids (particularly C-17 alkylated @DRUG$ such as oxymetholone, @DRUG$, norethandrolone, and similar compounds) may increase the risk of edema.", "LBL": "0", "DRUGA": ["androgens", "group", "47-55"], "DRUGB": ["methandrostenolone", "drug", "79-96"]}
{"ID": "DDI-DrugBank.d526.s19.p6", "TEXT1": "The use of anabolic steroids (particularly C-17 alkylated @DRUG$ such as oxymetholone, methandrostenolone, @DRUG$, and similar compounds) may enhance the tendency toward edema.", "LBL": "0", "DRUGA": ["androgens", "group", "47-55"], "DRUGB": ["norethandrolone", "drug", "99-113"]}
{"ID": "DDI-DrugBank.d526.s19.p7", "TEXT1": "Anabolic steroids (such as @DRUG$, @DRUG$, norethandrolone, and similar compounds) may enhance the tendency toward edema.", "LBL": "0", "DRUGA": ["oxymetholone", "drug", "65-76"], "DRUGB": ["methandrostenolone", "drug", "79-96"]}
{"ID": "DDI-DrugBank.d526.s19.p8", "TEXT1": "Some anabolic steroids (particularly C-17 alkylated androgens such as @DRUG$, methandrostenolone, @DRUG$, and similar compounds) have been associated with an increased tendency toward edema.", "LBL": "0", "DRUGA": ["oxymetholone", "drug", "65-76"], "DRUGB": ["norethandrolone", "drug", "99-113"]}
{"ID": "DDI-DrugBank.d526.s19.p9", "TEXT1": "Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, @DRUG$, @DRUG$, and similar compounds) are associated with an increased risk of edema.", "LBL": "0", "DRUGA": ["methandrostenolone", "drug", "79-96"], "DRUGB": ["norethandrolone", "drug", "99-113"]}
{"ID": "DDI-DrugBank.d526.s24.p0", "TEXT1": "When @DRUG$ therapy is initiated, it may be necessary to reduce the dosage of @DRUG$, and increased amounts may be required when estrogen therapy is discontinued.", "LBL": "0", "DRUGA": ["estrogen", "group", "5-12"], "DRUGB": ["corticosteroid", "group", "51-64"]}
{"ID": "DDI-DrugBank.d526.s24.p1", "TEXT1": "If you start taking @DRUG$, you may need to reduce your dosage of corticosteroids. And if you stop taking @DRUG$, you may need to increase your steroid dosage.", "LBL": "0", "DRUGA": ["estrogen", "group", "5-12"], "DRUGB": ["estrogen", "group", "133-140"]}
{"ID": "DDI-DrugBank.d526.s24.p2", "TEXT1": "When estrogen therapy is initiated, it may be necessary to reduce the dosage of @DRUG$, and when estrogen therapy is ended, increased amounts of @DRUG$ may be required.", "LBL": "0", "DRUGA": ["corticosteroid", "group", "51-64"], "DRUGB": ["estrogen", "group", "133-140"]}
{"ID": "DDI-DrugBank.d181.s0.p0", "TEXT1": "It is recommended to use caution when taking @DRUG$ or other @DRUG$ concurrently as this may result in uterine hypertonus. This could cause uterine rupture or cervical laceration, especially if there is inadequate cervical dilatation.", "LBL": "0", "DRUGA": ["Oxytocin", "drug", "0-7"], "DRUGB": ["oxytocics", "group", "18-26"]}
{"ID": "DDI-DrugBank.d181.s0.p1", "TEXT1": "There is a possibility that concurrent use of @DRUG$ with other oxytocics may result in uterine hypertonus, which could potentially cause uterine rupture or cervical laceration, especially if there is inadequate cervical dilatation.", "LBL": "DDI-effect", "DRUGA": ["Oxytocin", "drug", "0-7"], "DRUGB": ["dinoprost", "drug", "49-57"]}
{"ID": "DDI-DrugBank.d181.s0.p2", "TEXT1": "The use of oxytocin or other @DRUG$ in conjunction with @DRUG$ may result in uterine hypertonus, which could lead to uterine rupture or cervical laceration, especially if cervical dilatation is insufficient.", "LBL": "DDI-effect", "DRUGA": ["oxytocics", "group", "18-26"], "DRUGB": ["dinoprost", "drug", "49-57"]}
{"ID": "DDI-DrugBank.d187.s2.p0", "TEXT1": "A patient receiving Isoniazid reportedly experienced severe @DRUG$ toxicity.", "LBL": "0", "DRUGA": ["Acetaminophen", "drug", "0-12"], "DRUGB": ["acetaminophen", "drug", "34-46"]}
{"ID": "DDI-DrugBank.d187.s2.p1", "TEXT1": "A report of severe acetaminophen toxicity was reported in a patient receiving @DRUG$.", "LBL": "0", "DRUGA": ["Acetaminophen", "drug", "0-12"], "DRUGB": ["Isoniazid", "drug", "93-101"]}
{"ID": "DDI-DrugBank.d187.s2.p2", "TEXT1": "A case of severe @DRUG$ toxicity was reported in a patient taking @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["acetaminophen", "drug", "34-46"], "DRUGB": ["Isoniazid", "drug", "93-101"]}
{"ID": "DDI-DrugBank.d187.s3.p0", "TEXT1": "The toxicity may have resulted from an interaction between @DRUG$ and @DRUG$. It is believed that there may be a molecular basis for this interaction.", "LBL": "DDI-effect", "DRUGA": ["isoniazid", "drug", "102-110"], "DRUGB": ["acetaminophen", "drug", "116-128"]}
{"ID": "DDI-DrugBank.d187.s5.p0", "TEXT1": "It has been suggested that @DRUG$ may cause induction of P-450IIE1 in the patients liver, resulting in increased conversion of the ingested @DRUG$ to its toxic metabolites.", "LBL": "DDI-mechanism", "DRUGA": ["isoniazid", "drug", "38-46"], "DRUGB": ["acetaminophen", "drug", "170-182"]}
{"ID": "DDI-DrugBank.d187.s7.p0", "TEXT1": "@DRUG$: @DRUG$ may slow the metabolism of carbamazepine and increase its serum levels. Carbamazepine levels should be determined prior to concurrent administration with isoniazid, and signs and symptoms of carbamazepine toxicity should be monitored closely. The dosage of the anticonvulsant may need to be adjusted.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["Isoniazid", "drug", "15-23"]}
{"ID": "DDI-DrugBank.d187.s7.p1", "TEXT1": "Isoniazid may interfere with the metabolism of @DRUG$, potentially increasing its serum levels. Therefore, it's important to monitor carbamazepine levels closely when taking these medications concurrently, and to adjust the dosage of the anticonvulsant as needed.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["carbamazepine", "drug", "60-72"]}
{"ID": "DDI-DrugBank.d187.s7.p2", "TEXT1": "When isoniazid and carbamazepine are taken together, isoniazid can slow down the metabolism of carbamazepine and cause an increase in its serum levels. Therefore, it is important to determine the @DRUG$ levels prior to concurrent administration with isoniazid, and to closely monitor for signs and symptoms of carbamazepine toxicity. The dosage of the anticonvulsant may need to be adjusted as appropriate.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["Carbamazepine", "drug", "104-116"]}
{"ID": "DDI-DrugBank.d187.s7.p3", "TEXT1": "Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels. Therefore, carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["isoniazid", "drug", "186-194"]}
{"ID": "DDI-DrugBank.d187.s7.p4", "TEXT1": "If you're taking isoniazid, be aware that it can increase the level of carbamazepine in your blood. Check with your doctor to have your carbamazepine levels checked before starting isoniazid, and during treatment watch for signs of @DRUG$ toxicity. Your doctor may need to adjust the dose of your anticonvulsant medication.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["carbamazepine", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d187.s7.p5", "TEXT1": "@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels. Carbamazepine levels should be determined prior to concurrent administration with isoniazid, and signs and symptoms of carbamazepine toxicity should be monitored closely. Appropriate dosage adjustment of the @DRUG$ may be necessary.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s7.p6", "TEXT1": "Carbamazepine: @DRUG$ is known to slow the metabolism of @DRUG$ and increase its serum levels. Carbamazepine levels should be determined prior to concurrent administration with isoniazid. Signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "DDI-mechanism", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["carbamazepine", "drug", "60-72"]}
{"ID": "DDI-DrugBank.d187.s7.p7", "TEXT1": "Carbamazepine: @DRUG$ is thought to slow the metabolism of carbamazepine and increase its serum levels. @DRUG$ levels should be determined prior to concurrent administration with isoniazid. Signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["Carbamazepine", "drug", "104-116"]}
{"ID": "DDI-DrugBank.d187.s7.p8", "TEXT1": "Carbamazepine: @DRUG$ is known to reduce the metabolism of carbamazepine, which may lead to increased serum levels. Therefore, carbamazepine levels should be checked before starting concurrent administration with @DRUG$. In addition, signs and symptoms of carbamazepine toxicity should be monitored closely, and the dosage of the anticonvulsant should be adjusted as necessary.", "LBL": "0", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["isoniazid", "drug", "186-194"]}
{"ID": "DDI-DrugBank.d187.s7.p9", "TEXT1": "If you are taking @DRUG$, it is important to be aware that it can potentially slow down the metabolism of carbamazepine. This could result in higher serum levels of carbamazepine, so it is important to have your levels checked before starting this medication. Additionally, closely monitor for signs and symptoms of @DRUG$ toxicity, and adjust the anticonvulsant dosage accordingly.", "LBL": "0", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["carbamazepine", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d187.s7.p10", "TEXT1": "Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine which may lead to increased carbamazepine serum levels. Therefore, carbamazepine levels should be determined prior to concurrent administration with isoniazid. In addition, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.", "LBL": "0", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s7.p11", "TEXT1": "Carbamazepine is known to slow the metabolism of @DRUG$, and increased levels of the latter have been reported with concurrent administration of isoniazid. Therefore, @DRUG$ levels should be determined prior to starting isoniazid, and signs and symptoms of carbamazepine toxicity should be monitored closely. Appropriate dosage adjustment of the anticonvulsant may be necessary.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "60-72"], "DRUGB": ["Carbamazepine", "drug", "104-116"]}
{"ID": "DDI-DrugBank.d187.s7.p12", "TEXT1": "Carbamazepine is known to slow the metabolism of isoniazid, and concurrent administration of the two drugs can increase serum levels of carbamazepine. Carbamazepine levels should be determined prior to starting isoniazid, and signs and symptoms of carbamazepine toxicity should be monitored closely. Appropriate dosage adjustment of the anticonvulsant may be necessary.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "60-72"], "DRUGB": ["isoniazid", "drug", "186-194"]}
{"ID": "DDI-DrugBank.d187.s7.p13", "TEXT1": "Carbamazepine: Isoniazid can reduce the metabolism of @DRUG$ and lead to higher carbamazepine levels in the blood. Therefore, it's important to have carbamazepine levels checked before starting isoniazid, and to closely monitor for signs and symptoms of @DRUG$ toxicity during treatment. The dose of the anticonvulsant may need to be adjusted if toxicity occurs.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "60-72"], "DRUGB": ["carbamazepine", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d187.s7.p14", "TEXT1": "Concurrent administration of isoniazid and carbamazepine can lead to increased serum levels of carbamazepine. Carbamazepine levels should be monitored closely when these two medications are taken together, and the dose of carbamazepine should be adjusted as needed.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "60-72"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s7.p15", "TEXT1": "Carbamazepine: Isoniazid can slow the metabolism of carbamazepine and increase its serum levels. @DRUG$ levels should be determined before starting concurrent administration with @DRUG$. Closely monitor signs and symptoms of carbamazepine toxicity and make appropriate dosage adjustments to the anticonvulsant as needed.", "LBL": "DDI-advise", "DRUGA": ["Carbamazepine", "drug", "104-116"], "DRUGB": ["isoniazid", "drug", "186-194"]}
{"ID": "DDI-DrugBank.d187.s7.p16", "TEXT1": "Carbamazepine is known to slow the metabolism of isoniazid and increase its serum levels. Therefore, @DRUG$ levels should be determined prior to concurrent administration with isoniazid, and signs and symptoms of @DRUG$ toxicity should be monitored closely. Appropriate dosage adjustment of the anticonvulsant may be necessary.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "104-116"], "DRUGB": ["carbamazepine", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d187.s7.p17", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$. Therefore, @DRUG$ levels should be determined prior to concurrent administration with isoniazid, and signs and symptoms of carbamazepine toxicity should be monitored closely. Also, appropriate dosage adjustment of the @DRUG$ should be made.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "104-116"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s7.p18", "TEXT1": "The concurrent administration of carbamazepine and isoniazid is not recommended. Carbamazepine levels should be monitored closely when taking isoniazid, and the dosage of the anticonvulsant may need to be adjusted.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "186-194"], "DRUGB": ["carbamazepine", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d187.s7.p19", "TEXT1": "The metabolism of carbamazepine is known to be slowed by isoniazid, which may increase its serum levels. Carbamazepine levels should be monitored closely while taking @DRUG$ to adjust dosage as needed.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "186-194"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s7.p20", "TEXT1": "Concurrent administration of isoniazid and carbamazepine is known to slow the metabolism of carbamazepine and increase its serum levels. Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the drug should be made.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "219-231"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s8.p0", "TEXT1": "The potential for an interaction between @DRUG$ and Isoniazid exists.", "LBL": "0", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["Ketoconazole", "drug", "39-50"]}
{"ID": "DDI-DrugBank.d187.s8.p1", "TEXT1": "@DRUG$: There is a potential for an interaction between Ketoconazole and @DRUG$.", "LBL": "0", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["Isoniazid", "drug", "56-64"]}
{"ID": "DDI-DrugBank.d187.s8.p2", "TEXT1": "There is potential for an interaction between ketoconazole and @DRUG$.", "LBL": "DDI-int", "DRUGA": ["Ketoconazole", "drug", "39-50"], "DRUGB": ["Isoniazid", "drug", "56-64"]}
{"ID": "DDI-DrugBank.d187.s9.p0", "TEXT1": "@DRUG$: @DRUG$ may help to increase serum levels of phenytoin.", "LBL": "0", "DRUGA": ["Phenytoin", "drug", "0-8"], "DRUGB": ["Isoniazid", "drug", "11-19"]}
{"ID": "DDI-DrugBank.d187.s9.p1", "TEXT1": "@DRUG$: Isoniazid may increase the serum levels of @DRUG$.", "LBL": "0", "DRUGA": ["Phenytoin", "drug", "0-8"], "DRUGB": ["phenytoin", "drug", "50-58"]}
{"ID": "DDI-DrugBank.d187.s9.p2", "TEXT1": "Phenytoin: @DRUG$ may slightly increase serum levels of @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["Isoniazid", "drug", "11-19"], "DRUGB": ["phenytoin", "drug", "50-58"]}
{"ID": "DDI-DrugBank.d187.s10.p0", "TEXT1": "To avoid @DRUG$ intoxication, it is important to adjust the @DRUG$ dosage appropriately.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "9-17"], "DRUGB": ["anticonvulsant", "group", "63-76"]}
{"ID": "DDI-DrugBank.d187.s11.p0", "TEXT1": "Concomitant administration of @DRUG$ and @DRUG$ may cause slightly elevated plasma levels of theophylline in some instances, and a slight decrease in the elimination of isoniazid.", "LBL": "DDI-mechanism", "DRUGA": ["isoniazid", "drug", "74-82"], "DRUGB": ["theophylline", "drug", "88-99"]}
{"ID": "DDI-DrugBank.d187.s11.p1", "TEXT1": "A recent study has shown that the concurrent administration of @DRUG$ and theophylline may cause elevated plasma levels of @DRUG$, and in some cases a slight decrease in the elimination of isoniazid.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "74-82"], "DRUGB": ["theophylline", "drug", "137-148"]}
{"ID": "DDI-DrugBank.d187.s11.p2", "TEXT1": "A recent study has shown that the administration of @DRUG$ and theophylline concurrently may lead to elevated plasma levels of theophylline. In some cases, there may also be a slight decrease in the elimination of @DRUG$.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "74-82"], "DRUGB": ["isoniazid", "drug", "213-221"]}
{"ID": "DDI-DrugBank.d187.s11.p3", "TEXT1": "Recent studies have shown that the concurrent use of isoniazid and @DRUG$ may cause elevated plasma levels of @DRUG$. In some cases, there may also be a slight decrease in the elimination of isoniazid. Therefore, caution is advised if these two drugs are used together.", "LBL": "0", "DRUGA": ["theophylline", "drug", "88-99"], "DRUGB": ["theophylline", "drug", "137-148"]}
{"ID": "DDI-DrugBank.d187.s11.p4", "TEXT1": "A recent study has shown that administration of isoniazid and @DRUG$ concurrently may lead to elevated plasma levels of theophylline. In some cases, there may also be a slight decrease in the elimination of @DRUG$.", "LBL": "0", "DRUGA": ["theophylline", "drug", "88-99"], "DRUGB": ["isoniazid", "drug", "213-221"]}
{"ID": "DDI-DrugBank.d187.s11.p5", "TEXT1": "Theophylline: A recent study has shown that concomitant administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of theophylline.", "LBL": "0", "DRUGA": ["theophylline", "drug", "137-148"], "DRUGB": ["isoniazid", "drug", "213-221"]}
{"ID": "DDI-DrugBank.d187.s12.p0", "TEXT1": "Since the therapeutic range of @DRUG$ is relatively narrow, @DRUG$ serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.", "LBL": "0", "DRUGA": ["theophylline", "drug", "31-42"], "DRUGB": ["theophylline", "drug", "54-65"]}
{"ID": "DDI-DrugBank.d187.s12.p1", "TEXT1": "The therapeutic range of @DRUG$ is narrow, so it's important to closely monitor theophylline serum levels and adjust the @DRUG$ dosage accordingly.", "LBL": "0", "DRUGA": ["theophylline", "drug", "31-42"], "DRUGB": ["theophylline", "drug", "147-158"]}
{"ID": "DDI-DrugBank.d187.s12.p2", "TEXT1": "If @DRUG$ and @DRUG$ are used together, it is important to monitor theophylline serum levels closely and make appropriate dosage adjustments.", "LBL": "0", "DRUGA": ["theophylline", "drug", "54-65"], "DRUGB": ["theophylline", "drug", "147-158"]}
{"ID": "DDI-DrugBank.d187.s13.p0", "TEXT1": "One recent case study has suggested that there may be an increase in the plasma level of @DRUG$ when it is co-administered with isoniazid.", "LBL": "0", "DRUGA": ["Valproate", "drug", "0-8"], "DRUGB": ["valproate", "drug", "84-92"]}
{"ID": "DDI-DrugBank.d187.s13.p1", "TEXT1": "There is a possibility that taking @DRUG$ with valproate might increase the level of valproate in the blood.", "LBL": "0", "DRUGA": ["Valproate", "drug", "0-8"], "DRUGB": ["isoniazid", "drug", "120-128"]}
{"ID": "DDI-DrugBank.d187.s13.p2", "TEXT1": "A recent case study has suggested that when valproate is taken with @DRUG$, there may be an increase in the level of @DRUG$ in the blood.", "LBL": "DDI-mechanism", "DRUGA": ["valproate", "drug", "84-92"], "DRUGB": ["isoniazid", "drug", "120-128"]}
{"ID": "DDI-DrugBank.d187.s14.p0", "TEXT1": "Plasma @DRUG$ concentration should be monitored when @DRUG$ and valproate are co administered, and appropriate dosage adjustments of valproate may be necessary.", "LBL": "0", "DRUGA": ["valproate", "drug", "7-15"], "DRUGB": ["isoniazid", "drug", "56-64"]}
{"ID": "DDI-DrugBank.d187.s14.p1", "TEXT1": "When isoniazid and @DRUG$ are co administered, plasma @DRUG$ concentration should be monitored, and appropriate dosage adjustments of valproate should be made.", "LBL": "0", "DRUGA": ["valproate", "drug", "7-15"], "DRUGB": ["valproate", "drug", "70-78"]}
{"ID": "DDI-DrugBank.d187.s14.p2", "TEXT1": "When isoniazid and valproate are co administered, plasma @DRUG$ concentration should be monitored, and appropriate dosage adjustments of @DRUG$ should be made.", "LBL": "0", "DRUGA": ["valproate", "drug", "7-15"], "DRUGB": ["valproate", "drug", "139-147"]}
{"ID": "DDI-DrugBank.d187.s14.p3", "TEXT1": "It is recommended that plasma valproate concentration be monitored when @DRUG$ and @DRUG$ are co administered, and appropriate dosage adjustments of valproate be made accordingly.", "LBL": "DDI-advise", "DRUGA": ["isoniazid", "drug", "56-64"], "DRUGB": ["valproate", "drug", "70-78"]}
{"ID": "DDI-DrugBank.d187.s14.p4", "TEXT1": "If @DRUG$ and valproate are used together, it is recommended to monitor plasma valproate concentration and make appropriate dosage adjustments to @DRUG$.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "56-64"], "DRUGB": ["valproate", "drug", "139-147"]}
{"ID": "DDI-DrugBank.d187.s14.p5", "TEXT1": "When isoniazid and @DRUG$ are co administered, plasma valproate concentration should be monitored. Appropriate dosage adjustments of @DRUG$ should be made.", "LBL": "0", "DRUGA": ["valproate", "drug", "70-78"], "DRUGB": ["valproate", "drug", "139-147"]}
{"ID": "DDI-DrugBank.d323.s0.p0", "TEXT1": "Co-administration of @DRUG$ and @DRUG$ or other agents that interfere with neuromuscular transmission should be done with caution, as the effect of the toxin may be increased.", "LBL": "DDI-advise", "DRUGA": ["MYOBLOC", "brand", "21-27"], "DRUGB": ["aminoglycosides", "group", "33-47"]}
{"ID": "DDI-DrugBank.d323.s0.p1", "TEXT1": "The effect of the toxin may be potentiated when co-administered with @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$). Therefore, this combination should be used with caution.", "LBL": "DDI-advise", "DRUGA": ["MYOBLOC", "brand", "21-27"], "DRUGB": ["curare-like compounds", "group", "116-136"]}
{"ID": "DDI-DrugBank.d323.s0.p2", "TEXT1": "If you are taking @DRUG$ at the same time as aminoglycosides or other agents that interfere with neuromuscular transmission (e.g., curare-like compounds), please be cautious, as the effect of the @DRUG$ may be magnified.", "LBL": "0", "DRUGA": ["MYOBLOC", "brand", "21-27"], "DRUGB": ["toxin", "drug", "198-202"]}
{"ID": "DDI-DrugBank.d323.s0.p3", "TEXT1": "Co-administration of MYOBLOC and @DRUG$ may potentiate the effect of the toxin. Therefore, it should be performed with caution when @DRUG$ or other agents interfering with neuromuscular transmission are present.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "33-47"], "DRUGB": ["curare-like compounds", "group", "116-136"]}
{"ID": "DDI-DrugBank.d323.s0.p4", "TEXT1": "Co-administration of MYOBLOC and @DRUG$ should be done with caution, as the effect of the @DRUG$ may be increased.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "33-47"], "DRUGB": ["toxin", "drug", "198-202"]}
{"ID": "DDI-DrugBank.d323.s0.p5", "TEXT1": "Co-administration of MYOBLOC and aminoglycosides or other agents that interfere with neuromuscular transmission (e.g., @DRUG$) should be done with caution, as @DRUG$ may potentiate the effect.", "LBL": "0", "DRUGA": ["curare-like compounds", "group", "116-136"], "DRUGB": ["toxin", "drug", "198-202"]}
{"ID": "DDI-DrugBank.d289.s6.p0", "TEXT1": "There is an interaction between bosentan and the oral contraceptive Ortho-Novum, which can result in decreased levels of norethindrone and ethinyl estradiol.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["Contraceptives", "group", "82-95"]}
{"ID": "DDI-DrugBank.d289.s6.p1", "TEXT1": "In common with other @DRUG$, AUGMENTIN XR may change the efficacy of oral hormonal contraceptives. An interaction study showed that co-administration of @DRUG$ and the oral contraceptive Ortho-Novum resulted in average decreases of norethindrone and ethinyl estradiol levels of 14% and 31% respectively.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["bosentan", "drug", "158-165"]}
{"ID": "DDI-DrugBank.d289.s6.p2", "TEXT1": "The administration of bosentan and the oral @DRUG$ Ortho-Novum was shown to decrease norethindrone and ethinyl estradiol levels by an average of 14% and 31% respectively.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["hormonal contraceptive", "group", "180-201"]}
{"ID": "DDI-DrugBank.d289.s6.p3", "TEXT1": "@DRUG$ may reduce the levels of other drugs in the body, including oral, injectable, transdermal, and implantable contraceptives. In one study, co-administration of bosentan and the oral contraceptive @DRUG$ resulted in decreased levels of norethindrone (14%) and ethinyl estradiol (31%).", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["Ortho-Novum", "brand", "203-213"]}
{"ID": "DDI-DrugBank.d289.s6.p4", "TEXT1": "An interaction study showed that taking bosentan together with the oral contraceptive Ortho-Novum resulted in average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31% respectively. Therefore, caution is advised if these two medications are used together.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["norethindrone", "drug", "245-257"]}
{"ID": "DDI-DrugBank.d289.s6.p5", "TEXT1": "@DRUG$, co-administered with bosentan, may decrease the levels of the oral hormonal contraceptive Ortho-Novum by an average of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s6.p6", "TEXT1": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable @DRUG$, may interact with @DRUG$. An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "82-95"], "DRUGB": ["bosentan", "drug", "158-165"]}
{"ID": "DDI-DrugBank.d289.s6.p7", "TEXT1": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable @DRUG$, may interact with bosentan. An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively. Therefore, caution is advised when using hormonal contraceptives in combination with bosentan.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "82-95"], "DRUGB": ["hormonal contraceptive", "group", "180-201"]}
{"ID": "DDI-DrugBank.d289.s6.p8", "TEXT1": "An interaction study showed that taking bosentan and the oral hormonal contraceptive @DRUG$ together caused average decreases of norethindrone and ethinyl estradiol levels of 14% and 31% respectively.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "82-95"], "DRUGB": ["Ortho-Novum", "brand", "203-213"]}
{"ID": "DDI-DrugBank.d289.s6.p9", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study showed that taking bosentan and the oral contraceptive Ortho-Novum together resulted in average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31% respectively.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "82-95"], "DRUGB": ["norethindrone", "drug", "245-257"]}
{"ID": "DDI-DrugBank.d289.s6.p10", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively. However, these levels are still within the therapeutic range and are not expected to have any clinically significant effect.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "82-95"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s6.p11", "TEXT1": "It is recommended to use caution when taking @DRUG$ and @DRUG$ together, as an interaction study showed that on average, levels of norethindrone and ethinyl estradiol decreased by 14% and 31% respectively.", "LBL": "0", "DRUGA": ["bosentan", "drug", "158-165"], "DRUGB": ["hormonal contraceptive", "group", "180-201"]}
{"ID": "DDI-DrugBank.d289.s6.p12", "TEXT1": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives, may interact with @DRUG$. An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "158-165"], "DRUGB": ["Ortho-Novum", "brand", "203-213"]}
{"ID": "DDI-DrugBank.d289.s6.p13", "TEXT1": "An interaction study found that taking @DRUG$ and the oral hormonal contraceptive Ortho-Novum together led to average decreases in @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["bosentan", "drug", "158-165"], "DRUGB": ["norethindrone", "drug", "245-257"]}
{"ID": "DDI-DrugBank.d289.s6.p14", "TEXT1": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives, may interact with @DRUG$. An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["bosentan", "drug", "158-165"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s6.p15", "TEXT1": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["hormonal contraceptive", "group", "180-201"], "DRUGB": ["Ortho-Novum", "brand", "203-213"]}
{"ID": "DDI-DrugBank.d289.s6.p16", "TEXT1": "An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["hormonal contraceptive", "group", "180-201"], "DRUGB": ["norethindrone", "drug", "245-257"]}
{"ID": "DDI-DrugBank.d289.s6.p17", "TEXT1": "A study showed that taking bosentan and the oral @DRUG$ Ortho-Novum together caused the levels of norethindrone and @DRUG$ to decrease by an average of 14% and 31% respectively.", "LBL": "0", "DRUGA": ["hormonal contraceptive", "group", "180-201"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s6.p18", "TEXT1": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases in @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Ortho-Novum", "brand", "203-213"], "DRUGB": ["norethindrone", "drug", "245-257"]}
{"ID": "DDI-DrugBank.d289.s6.p19", "TEXT1": "An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ resulted in average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Ortho-Novum", "brand", "203-213"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s6.p20", "TEXT1": "An interaction study showed that taking bosentan with the oral hormonal contraceptive Ortho-Novum caused the levels of @DRUG$ and @DRUG$ to go down by an average of 14% and 31% respectively.", "LBL": "0", "DRUGA": ["norethindrone", "drug", "245-257"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s8.p0", "TEXT1": "Therefore, it is recommended to exercise caution when using @DRUG$ alongside @DRUG$. This is because @DRUG$ may not be as effective when taken together.", "LBL": "DDI-effect", "DRUGA": ["hormonal contraceptives", "group", "11-33"], "DRUGB": ["TRACLEER", "brand", "125-132"]}
{"ID": "DDI-DrugBank.d289.s10.p0", "TEXT1": "There is an increased risk of side effects when taking @DRUG$ and @DRUG$ together, as studies have shown that the concentration of @DRUG$ in the body may be increased by up to 30-fold.", "LBL": "0", "DRUGA": ["Cyclosporine A", "drug", "62-75"], "DRUGB": ["bosentan", "drug", "155-162"]}
{"ID": "DDI-DrugBank.d289.s11.p0", "TEXT1": "The steady-state plasma concentration of @DRUG$ was a few-fold higher in the presence of the drug, compared to when it was absent.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "13-20"], "DRUGB": ["cyclosporine A", "drug", "92-105"]}
{"ID": "DDI-DrugBank.d289.s12.p0", "TEXT1": "The concomitant administration of @DRUG$ and @DRUG$ should be avoided.", "LBL": "DDI-advise", "DRUGA": ["bosentan", "drug", "34-41"], "DRUGB": ["cyclosporine A", "drug", "47-60"]}
{"ID": "DDI-DrugBank.d289.s13.p0", "TEXT1": "The plasma concentrations of @DRUG$ (a CYP3A4 substrate) kept at approximately 50% when co-administered with @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "21-28"], "DRUGB": ["cyclosporine A", "drug", "69-82"]}
{"ID": "DDI-DrugBank.d289.s14.p0", "TEXT1": "There is no data to suggest that co-administration of @DRUG$ and bosentan is safe or effective in humans.", "LBL": "0", "DRUGA": ["Tacrolimus", "drug", "0-9"], "DRUGB": ["tacrolimus", "drug", "33-42"]}
{"ID": "DDI-DrugBank.d289.s14.p1", "TEXT1": "There is no data available on the co-administration of tacrolimus and @DRUG$ in humans.", "LBL": "0", "DRUGA": ["Tacrolimus", "drug", "0-9"], "DRUGB": ["bosentan", "drug", "48-55"]}
{"ID": "DDI-DrugBank.d289.s14.p2", "TEXT1": "There is no data currently available on the co-administration of tacrolimus and @DRUG$ in humans.", "LBL": "0", "DRUGA": ["tacrolimus", "drug", "33-42"], "DRUGB": ["bosentan", "drug", "48-55"]}
{"ID": "DDI-DrugBank.d289.s15.p0", "TEXT1": "Co-administration of @DRUG$ and @DRUG$ resulted in increased plasma concentrations of bosentan in animals.", "LBL": "DDI-mechanism", "DRUGA": ["tacrolimus", "drug", "21-30"], "DRUGB": ["bosentan", "drug", "36-43"]}
{"ID": "DDI-DrugBank.d289.s15.p1", "TEXT1": "There was a marked increase in plasma concentrations of @DRUG$ when @DRUG$ and bosentan were co-administered to animals.", "LBL": "0", "DRUGA": ["tacrolimus", "drug", "21-30"], "DRUGB": ["bosentan", "drug", "101-108"]}
{"ID": "DDI-DrugBank.d289.s15.p2", "TEXT1": "When tacrolimus and @DRUG$ were given together, there was a significant increase in the amount of @DRUG$ in the animals' blood.", "LBL": "0", "DRUGA": ["bosentan", "drug", "36-43"], "DRUGB": ["bosentan", "drug", "101-108"]}
{"ID": "DDI-DrugBank.d289.s16.p0", "TEXT1": "If @DRUG$ and @DRUG$ are used together, caution should be exercised.", "LBL": "DDI-advise", "DRUGA": ["tacrolimus", "drug", "31-40"], "DRUGB": ["bosentan", "drug", "46-53"]}
{"ID": "DDI-DrugBank.d289.s17.p0", "TEXT1": "In patients receiving concomitant therapy with @DRUG$, an increased risk of elevated liver aminotransferases was observed.", "LBL": "0", "DRUGA": ["Glyburide", "drug", "0-8"], "DRUGB": ["glyburide", "drug", "125-133"]}
{"ID": "DDI-DrugBank.d289.s18.p0", "TEXT1": "Therefore, the concomitant administration of @DRUG$ and @DRUG$ should be avoided, and alternative hypoglycemic agents should be considered.", "LBL": "DDI-advise", "DRUGA": ["TRACLEER", "brand", "45-52"], "DRUGB": ["glyburide", "drug", "58-66"]}
{"ID": "DDI-DrugBank.d289.s18.p1", "TEXT1": "The concomitant administration of @DRUG$ and glyburide is not recommended, and alternative @DRUG$ should be considered.", "LBL": "0", "DRUGA": ["TRACLEER", "brand", "45-52"], "DRUGB": ["hypoglycemic agents", "group", "104-122"]}
{"ID": "DDI-DrugBank.d289.s18.p2", "TEXT1": "TRACLEER and @DRUG$ should not be taken together because it may decrease the effectiveness of @DRUG$. Alternative @DRUG$ should be considered.", "LBL": "0", "DRUGA": ["glyburide", "drug", "58-66"], "DRUGB": ["hypoglycemic agents", "group", "104-122"]}
{"ID": "DDI-DrugBank.d289.s19.p0", "TEXT1": "When @DRUG$ is taken at the same time as milk or milk products, the plasma concentrations of @DRUG$ are kept at approximately 40%.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "21-28"], "DRUGB": ["glyburide", "drug", "69-77"]}
{"ID": "DDI-DrugBank.d289.s21.p0", "TEXT1": "It is expected that @DRUG$ will also reduce plasma concentrations of other oral @DRUG$ that are predominantly metabolized by CYP2C9 or CYP3A4.", "LBL": "DDI-mechanism", "DRUGA": ["Bosentan", "drug", "0-7"], "DRUGB": ["hypoglycemic agents", "group", "72-90"]}
{"ID": "DDI-DrugBank.d289.s23.p0", "TEXT1": "When @DRUG$ 125 mg is administered twice daily alongside ketoconazole, a potent CYP3A4 inhibitor, the plasma concentrations of bosentan increase by approximately two-fold.", "LBL": "0", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["bosentan", "drug", "35-42"]}
{"ID": "DDI-DrugBank.d289.s23.p1", "TEXT1": "@DRUG$: Co-administration of bosentan 125 mg b.i.d. and @DRUG$, a potent CYP3A4 inhibitor, resulted in a few-fold increase in the plasma concentrations of bosentan.", "LBL": "0", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["ketoconazole", "drug", "62-73"]}
{"ID": "DDI-DrugBank.d289.s23.p2", "TEXT1": "CYP3A4 inhibitors like ketoconazole may increase the plasma concentrations of @DRUG$ when given together.", "LBL": "0", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["bosentan", "drug", "142-149"]}
{"ID": "DDI-DrugBank.d289.s23.p3", "TEXT1": "When ketoconazole, a potent CYP3A4 inhibitor, is co-administered with @DRUG$ 125 mg b.i.d., the plasma concentrations of bosentan increase by approximately 2-fold.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "35-42"], "DRUGB": ["ketoconazole", "drug", "62-73"]}
{"ID": "DDI-DrugBank.d289.s23.p4", "TEXT1": "Co-administration of @DRUG$ 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of @DRUG$ by approximately 2-fold.", "LBL": "0", "DRUGA": ["bosentan", "drug", "35-42"], "DRUGB": ["bosentan", "drug", "142-149"]}
{"ID": "DDI-DrugBank.d289.s23.p5", "TEXT1": "If @DRUG$ and @DRUG$ are used together, caution is advised as the combination may increase the plasma concentration of @DRUG$.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "62-73"], "DRUGB": ["bosentan", "drug", "142-149"]}
{"ID": "DDI-DrugBank.d289.s24.p0", "TEXT1": "No dose adjustment of @DRUG$ is necessary when taking it with @DRUG$, but the effects of @DRUG$ may be increased.", "LBL": "0", "DRUGA": ["bosentan", "drug", "22-29"], "DRUGB": ["bosentan", "drug", "70-77"]}
{"ID": "DDI-DrugBank.d289.s25.p0", "TEXT1": "@DRUG$ and Other @DRUG$: Co-administration of bosentan kept the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, at approximately 50%.", "LBL": "0", "DRUGA": ["Simvastatin", "drug", "0-10"], "DRUGB": ["Statins", "group", "22-28"]}
{"ID": "DDI-DrugBank.d289.s25.p1", "TEXT1": "@DRUG$ and Other Statins: Co-administration of @DRUG$ kept the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, at approximately half.", "LBL": "0", "DRUGA": ["Simvastatin", "drug", "0-10"], "DRUGB": ["bosentan", "drug", "52-59"]}
{"ID": "DDI-DrugBank.d289.s25.p2", "TEXT1": "If you are taking @DRUG$ and another statin medication, the absorption of @DRUG$ may be kept at approximately 50%.", "LBL": "0", "DRUGA": ["Simvastatin", "drug", "0-10"], "DRUGB": ["simvastatin", "drug", "100-110"]}
{"ID": "DDI-DrugBank.d289.s25.p3", "TEXT1": "You may want to exercise caution if you're taking simvastatin and another @DRUG$ medication together. Studies have shown that taking these drugs together can decrease the plasma concentrations of simvastatin by up to 50%.", "LBL": "0", "DRUGA": ["Statins", "group", "22-28"], "DRUGB": ["bosentan", "drug", "52-59"]}
{"ID": "DDI-DrugBank.d289.s25.p4", "TEXT1": "Simvastatin and Other @DRUG$: Co-administration of bosentan kept the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, at approximately half.", "LBL": "0", "DRUGA": ["Statins", "group", "22-28"], "DRUGB": ["simvastatin", "drug", "100-110"]}
{"ID": "DDI-DrugBank.d289.s25.p5", "TEXT1": "Simvastatin and Other Statins: Co-administration of @DRUG$ may keep the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, at approximately 50%.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "52-59"], "DRUGB": ["simvastatin", "drug", "100-110"]}
{"ID": "DDI-DrugBank.d289.s27.p0", "TEXT1": "Concomitant administration of @DRUG$ may reduce plasma concentrations of other @DRUG$ that are metabolized by CYP3A4, such as lovastatin and atorvastatin.", "LBL": "DDI-mechanism", "DRUGA": ["Bosentan", "drug", "0-7"], "DRUGB": ["statins", "group", "67-73"]}
{"ID": "DDI-DrugBank.d289.s27.p1", "TEXT1": "@DRUG$ may also reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as @DRUG$ and atorvastatin.", "LBL": "DDI-mechanism", "DRUGA": ["Bosentan", "drug", "0-7"], "DRUGB": ["lovastatin", "drug", "127-136"]}
{"ID": "DDI-DrugBank.d289.s27.p2", "TEXT1": "@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["Bosentan", "drug", "0-7"], "DRUGB": ["atorvastatin", "drug", "142-153"]}
{"ID": "DDI-DrugBank.d289.s27.p3", "TEXT1": "Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have metabolism through CYP3A4, such as @DRUG$ and atorvastatin.", "LBL": "0", "DRUGA": ["statins", "group", "67-73"], "DRUGB": ["lovastatin", "drug", "127-136"]}
{"ID": "DDI-DrugBank.d289.s27.p4", "TEXT1": "Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.", "LBL": "0", "DRUGA": ["statins", "group", "67-73"], "DRUGB": ["atorvastatin", "drug", "142-153"]}
{"ID": "DDI-DrugBank.d289.s27.p5", "TEXT1": "Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as @DRUG$ and @DRUG$.", "LBL": "0", "DRUGA": ["lovastatin", "drug", "127-136"], "DRUGB": ["atorvastatin", "drug", "142-153"]}
{"ID": "DDI-DrugBank.d289.s29.p0", "TEXT1": "Patients using CYP3A4 metabolized @DRUG$ should have cholesterol levels monitored after @DRUG$ is initiated to see if the statin dose needs adjusting.", "LBL": "DDI-advise", "DRUGA": ["statins", "group", "34-40"], "DRUGB": ["TRACLEER", "brand", "89-96"]}
{"ID": "DDI-DrugBank.d289.s29.p1", "TEXT1": "CYP3A4 metabolized @DRUG$ users should have their cholesterol levels monitored after starting TRACLEER to see if the @DRUG$ dose needs to be adjusted.", "LBL": "0", "DRUGA": ["statins", "group", "34-40"], "DRUGB": ["statin", "group", "130-135"]}
{"ID": "DDI-DrugBank.d289.s29.p2", "TEXT1": "CYP3A4 metabolized statin users should have their cholesterol levels monitored after starting @DRUG$. This will help to determine if the @DRUG$ dose needs to be adjusted.", "LBL": "0", "DRUGA": ["TRACLEER", "brand", "89-96"], "DRUGB": ["statin", "group", "130-135"]}
{"ID": "DDI-DrugBank.d289.s30.p0", "TEXT1": "The co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively. However, it is not known to what extent this may impact the efficacy of warfarin.", "LBL": "0", "DRUGA": ["Warfarin", "drug", "0-7"], "DRUGB": ["bosentan", "drug", "31-38"]}
{"ID": "DDI-DrugBank.d289.s30.p1", "TEXT1": "Co-administration of @DRUG$ decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.", "LBL": "0", "DRUGA": ["Warfarin", "drug", "0-7"], "DRUGB": ["S-warfarin", "drug", "109-118"]}
{"ID": "DDI-DrugBank.d289.s30.p2", "TEXT1": "The concomitant administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.", "LBL": "0", "DRUGA": ["Warfarin", "drug", "0-7"], "DRUGB": ["R-warfarin", "drug", "145-154"]}
{"ID": "DDI-DrugBank.d289.s30.p3", "TEXT1": "The concomitant administration of @DRUG$ 500 mg b.i.d. for 6 days may decrease the plasma concentrations of both @DRUG$ and R-warfarin.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "31-38"], "DRUGB": ["S-warfarin", "drug", "109-118"]}
{"ID": "DDI-DrugBank.d289.s30.p4", "TEXT1": "Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively. However, the concentrations of both drugs remained within the therapeutic range.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "31-38"], "DRUGB": ["R-warfarin", "drug", "145-154"]}
{"ID": "DDI-DrugBank.d289.s30.p5", "TEXT1": "Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both warfarin (a CYP2C9 substrate) and rivaroxaban (a CYP3A4 substrate) by 29 and 38%, respectively.", "LBL": "0", "DRUGA": ["S-warfarin", "drug", "109-118"], "DRUGB": ["R-warfarin", "drug", "145-154"]}
{"ID": "DDI-DrugBank.d289.s31.p0", "TEXT1": "There is no clinical evidence to suggest that taking @DRUG$ with @DRUG$ will have any effect on the dose of warfarin required. In fact, the need to adjust the warfarin dose during trials due to changes in INR or adverse events was similar in patients taking bosentan and those taking placebo.", "LBL": "0", "DRUGA": ["bosentan", "drug", "55-62"], "DRUGB": ["warfarin", "drug", "68-75"]}
{"ID": "DDI-DrugBank.d289.s31.p1", "TEXT1": "From clinical experience, it has been found that the concomitant administration of @DRUG$ and warfarin in patients with pulmonary arterial hypertension did not lead to clinically significant changes in INR or @DRUG$ dose (between baseline and the end of the clinical studies). Furthermore, the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.", "LBL": "0", "DRUGA": ["bosentan", "drug", "55-62"], "DRUGB": ["warfarin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d289.s31.p2", "TEXT1": "There was no clinically relevant difference seen in the INR or warfarin dose when @DRUG$ and warfarin were taken together by patients with pulmonary arterial hypertension. Also, the need to adjust the @DRUG$ dose during trials due to changes in INR or adverse events was similar in patients taking bosentan or placebo.", "LBL": "0", "DRUGA": ["bosentan", "drug", "55-62"], "DRUGB": ["warfarin", "drug", "262-269"]}
{"ID": "DDI-DrugBank.d289.s31.p3", "TEXT1": "The concomitant administration of @DRUG$ and warfarin did not result in clinically significant changes in INR or warfarin dose in patients with pulmonary arterial hypertension (based on data from clinical trials). There was also no difference in the need to adjust the warfarin dose during the trial due to changes in INR or adverse events between @DRUG$-treated and placebo patients.", "LBL": "0", "DRUGA": ["bosentan", "drug", "55-62"], "DRUGB": ["bosentan", "drug", "359-366"]}
{"ID": "DDI-DrugBank.d289.s31.p4", "TEXT1": "From clinical experience with co-administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension, no significant changes in INR or @DRUG$ dose (between baseline and the end of the clinical studies) were observed. In addition, the warfarin dose did not need to be changed during the trials due to changes in INR or adverse events, and this was similar among bosentan- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "68-75"], "DRUGB": ["warfarin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d289.s31.p5", "TEXT1": "There is clinical evidence that bosentan and @DRUG$ can be safely used together, with no significant changes in INR or warfarin dose noted. In fact, the need to adjust @DRUG$ dose during clinical trials due to changes in INR or adverse events was similar among bosentan- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "68-75"], "DRUGB": ["warfarin", "drug", "262-269"]}
{"ID": "DDI-DrugBank.d289.s31.p6", "TEXT1": "The clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension showed no significant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "68-75"], "DRUGB": ["bosentan", "drug", "359-366"]}
{"ID": "DDI-DrugBank.d289.s31.p7", "TEXT1": "Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension showed no clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "177-184"], "DRUGB": ["warfarin", "drug", "262-269"]}
{"ID": "DDI-DrugBank.d289.s31.p8", "TEXT1": "Clinical studies have shown that there is no significant difference in the INR or @DRUG$ dose (baseline vs. end of the clinical studies) when bosentan and warfarin are administered concomitantly. Additionally, the need to change the warfarin dose during clinical trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "177-184"], "DRUGB": ["bosentan", "drug", "359-366"]}
{"ID": "DDI-DrugBank.d289.s31.p9", "TEXT1": "Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension showed that there were no clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "262-269"], "DRUGB": ["bosentan", "drug", "359-366"]}
{"ID": "DDI-DrugBank.d289.s32.p0", "TEXT1": "No significant pharmacokinetic interactions were found between bosentan and digoxin or nimodipine, and losartan had no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["Nimodipine", "drug", "9-18"]}
{"ID": "DDI-DrugBank.d289.s32.p1", "TEXT1": "There is no significant effect on plasma levels of bosentan when taken with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["Losartan", "drug", "24-31"]}
{"ID": "DDI-DrugBank.d289.s32.p2", "TEXT1": "No significant drug interactions have been observed between @DRUG$, nimodipine and losartan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["Bosentan", "drug", "34-41"]}
{"ID": "DDI-DrugBank.d289.s32.p3", "TEXT1": "There are no significant pharmacokinetic interactions between bosentan and @DRUG$, nimodipine, or losartan. Losartan does not affect plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["digoxin", "drug", "96-102"]}
{"ID": "DDI-DrugBank.d289.s32.p4", "TEXT1": "There are no significant pharmacokinetic interactions between bosentan and either digoxin or @DRUG$. Additionally, losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["nimodipine", "drug", "108-117"]}
{"ID": "DDI-DrugBank.d289.s32.p5", "TEXT1": "Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p6", "TEXT1": "Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p7", "TEXT1": "There is no significant interaction between bosentan and digoxin or nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["Losartan", "drug", "24-31"]}
{"ID": "DDI-DrugBank.d289.s32.p8", "TEXT1": "Digoxin, @DRUG$ and Losartan: @DRUG$ has no significant pharmacokinetic interactions with these drugs, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["Bosentan", "drug", "34-41"]}
{"ID": "DDI-DrugBank.d289.s32.p9", "TEXT1": "There are no significant pharmacokinetic interactions between bosentan and digoxin, @DRUG$, or losartan. Therefore, losartan does not significantly affect plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["digoxin", "drug", "96-102"]}
{"ID": "DDI-DrugBank.d289.s32.p10", "TEXT1": "Bosentan does not have any significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan does not affect plasma levels of bosentan significantly.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["nimodipine", "drug", "108-117"]}
{"ID": "DDI-DrugBank.d289.s32.p11", "TEXT1": "Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p12", "TEXT1": "There are no significant pharmacokinetic interactions between bosentan and either digoxin or losartan. Nimodipine levels may be affected, but this is not thought to be clinically significant.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p13", "TEXT1": "There are no significant pharmacokinetic interactions between @DRUG$ and digoxin or nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Losartan", "drug", "24-31"], "DRUGB": ["Bosentan", "drug", "34-41"]}
{"ID": "DDI-DrugBank.d289.s32.p14", "TEXT1": "No significant pharmacokinetic interactions are expected between bosentan and either digoxin or nimodipine. Similarly, losartan is not expected to significantly affect plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Losartan", "drug", "24-31"], "DRUGB": ["digoxin", "drug", "96-102"]}
{"ID": "DDI-DrugBank.d289.s32.p15", "TEXT1": "There are no significant pharmacokinetic interactions between bosentan and digoxin or @DRUG$, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Losartan", "drug", "24-31"], "DRUGB": ["nimodipine", "drug", "108-117"]}
{"ID": "DDI-DrugBank.d289.s32.p16", "TEXT1": "Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Losartan", "drug", "24-31"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p17", "TEXT1": "Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine. Losartan has no significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["Losartan", "drug", "24-31"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p18", "TEXT1": "No significant pharmacokinetic interactions are observed between @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Bosentan", "drug", "34-41"], "DRUGB": ["digoxin", "drug", "96-102"]}
{"ID": "DDI-DrugBank.d289.s32.p19", "TEXT1": "There are no significant drug interactions between @DRUG$ and digoxin, nimodipine, or losartan. @DRUG$ does not affect the plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Bosentan", "drug", "34-41"], "DRUGB": ["nimodipine", "drug", "108-117"]}
{"ID": "DDI-DrugBank.d289.s32.p20", "TEXT1": "@DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Bosentan", "drug", "34-41"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p21", "TEXT1": "There are no significant pharmacokinetic interactions between @DRUG$ and digoxin or nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["Bosentan", "drug", "34-41"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p22", "TEXT1": "Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["digoxin", "drug", "96-102"], "DRUGB": ["nimodipine", "drug", "108-117"]}
{"ID": "DDI-DrugBank.d289.s32.p23", "TEXT1": "There are no significant pharmacokinetic interactions between bosentan and either digoxin or nimodipine, and bosentan has no significant effect on plasma levels of digoxin.", "LBL": "0", "DRUGA": ["digoxin", "drug", "96-102"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p24", "TEXT1": "There are no significant pharmacokinetic interactions between bosentan and @DRUG$, nimodipine, or losartan. plasma levels of @DRUG$ are not affected by losartan.", "LBL": "0", "DRUGA": ["digoxin", "drug", "96-102"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p25", "TEXT1": "Bosentan only has very minor interactions with digoxin and @DRUG$, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["nimodipine", "drug", "108-117"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p26", "TEXT1": "Bosentan does not have any significant pharmacokinetic interactions with digoxin and nimodipine, and losartan does not have any significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["nimodipine", "drug", "108-117"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p27", "TEXT1": "No significant pharmacokinetic interactions are anticipated if digoxin, nimodipine and losartan are used together with bosentan. @DRUG$ is not expected to have any significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["losartan", "drug", "124-131"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d5.s0.p0", "TEXT1": "There is limited data available on how @DRUG$ is affected by other drugs, or how @DRUG$ affects the metabolism of other drugs.", "LBL": "0", "DRUGA": ["WELLBUTRIN", "brand", "59-68"], "DRUGB": ["WELLBUTRIN", "brand", "187-196"]}
{"ID": "DDI-DrugBank.d5.s2.p0", "TEXT1": "In vitro studies suggest that @DRUG$ is largely metabolized to @DRUG$ by the CYP2B6 isoenzyme.", "LBL": "0", "DRUGA": ["bupropion", "drug", "31-39"], "DRUGB": ["hydroxybupropion", "drug_n", "69-84"]}
{"ID": "DDI-DrugBank.d5.s3.p0", "TEXT1": "There is a potential for a drug interaction between @DRUG$ and drugs that affect the CYP2B6 isoenzyme (e.g., @DRUG$ and cyclophosphamide).", "LBL": "DDI-int", "DRUGA": ["WELLBUTRIN", "brand", "63-72"], "DRUGB": ["orphenadrine", "drug", "124-135"]}
{"ID": "DDI-DrugBank.d5.s3.p1", "TEXT1": "There is a potential for a drug interaction between @DRUG$ and drugs that affect the CYP2B6 isoenzyme, such as orphenadrine and @DRUG$.", "LBL": "DDI-int", "DRUGA": ["WELLBUTRIN", "brand", "63-72"], "DRUGB": ["cyclophosphamide", "drug", "141-156"]}
{"ID": "DDI-DrugBank.d5.s3.p2", "TEXT1": "There is a potential for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., @DRUG$ and @DRUG$).", "LBL": "0", "DRUGA": ["orphenadrine", "drug", "124-135"], "DRUGB": ["cyclophosphamide", "drug", "141-156"]}
{"ID": "DDI-DrugBank.d5.s4.p0", "TEXT1": "There is no clear evidence that the @DRUG$ metabolite of @DRUG$ is produced by the cytochrome P450 isoenzymes.", "LBL": "0", "DRUGA": ["threohydrobupropion", "drug_n", "4-22"], "DRUGB": ["bupropion", "drug", "38-46"]}
{"ID": "DDI-DrugBank.d5.s5.p0", "TEXT1": "The effects of taking @DRUG$ at the same time as other drugs on the pharmacokinetics of @DRUG$ and its active metabolites were studied in 24 healthy young male volunteers.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "45-54"], "DRUGB": ["bupropion", "drug", "83-91"]}
{"ID": "DDI-DrugBank.d5.s6.p0", "TEXT1": "Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of @DRUG$, the pharmacokinetics of @DRUG$ and hydroxybupropion were similar.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "97-106"], "DRUGB": ["bupropion", "drug", "133-141"]}
{"ID": "DDI-DrugBank.d5.s6.p1", "TEXT1": "Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of @DRUG$, the pharmacokinetics of bupropion and @DRUG$ were similar.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "97-106"], "DRUGB": ["hydroxybupropion", "drug_n", "147-162"]}
{"ID": "DDI-DrugBank.d5.s6.p2", "TEXT1": "Based on the results of a study that looked at the pharmacokinetics of @DRUG$ and @DRUG$ with and without the addition of 800 mg cimetidine, it appears that cimetidine does not have an effect on the absorption or metabolism of these drugs.", "LBL": "0", "DRUGA": ["bupropion", "drug", "133-141"], "DRUGB": ["hydroxybupropion", "drug_n", "147-162"]}
{"ID": "DDI-DrugBank.d5.s7.p0", "TEXT1": "There were 16% and 32% increases in the AUC and Cmax, respectively, when @DRUG$ and @DRUG$ were administered together.", "LBL": "0", "DRUGA": ["threohydrobupropion", "drug_n", "105-123"], "DRUGB": ["erythrohydrobupropion", "drug_n", "129-149"]}
{"ID": "DDI-DrugBank.d5.s8.p0", "TEXT1": "While not systematically studied, it is possible that certain drugs may induce the metabolism of @DRUG$ (e.g., @DRUG$, phenobarbital, phenytoin).", "LBL": "DDI-mechanism", "DRUGA": ["bupropion", "drug", "77-85"], "DRUGB": ["carbamazepine", "drug", "94-106"]}
{"ID": "DDI-DrugBank.d5.s8.p1", "TEXT1": "While not systematically studied, it is possible that certain drugs may induce the metabolism of @DRUG$ (e.g., carbamazepine, @DRUG$, phenytoin).", "LBL": "DDI-mechanism", "DRUGA": ["bupropion", "drug", "77-85"], "DRUGB": ["phenobarbital", "drug", "109-121"]}
{"ID": "DDI-DrugBank.d5.s8.p2", "TEXT1": "Provided that no systematic studies have been conducted, it is possible that certain drugs may induce the metabolism of @DRUG$. Examples of such drugs include carbamazepine, phenobarbital, and @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["bupropion", "drug", "77-85"], "DRUGB": ["phenytoin", "drug", "124-132"]}
{"ID": "DDI-DrugBank.d5.s8.p3", "TEXT1": "Certain drugs may induce the metabolism of bupropion (e.g., @DRUG$, @DRUG$, phenytoin); however, this has not been systematically studied.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "94-106"], "DRUGB": ["phenobarbital", "drug", "109-121"]}
{"ID": "DDI-DrugBank.d5.s8.p4", "TEXT1": "Bupropion may be metabolized more quickly by certain drugs (e.g., @DRUG$, phenobarbital, @DRUG$), although this has not been systematically studied.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "94-106"], "DRUGB": ["phenytoin", "drug", "124-132"]}
{"ID": "DDI-DrugBank.d5.s8.p5", "TEXT1": "Certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, @DRUG$, @DRUG$), although this has not been systematically studied.", "LBL": "0", "DRUGA": ["phenobarbital", "drug", "109-121"], "DRUGB": ["phenytoin", "drug", "124-132"]}
{"ID": "DDI-DrugBank.d5.s12.p0", "TEXT1": "There are many drugs that are metabolized by the CYP2D6 isoenzyme, including most @DRUG$ (SSRIs, many @DRUG$), beta-blockers, antiarrhythmics, and antipsychotics.", "LBL": "0", "DRUGA": ["antidepressants", "group", "78-92"], "DRUGB": ["tricyclics", "group", "107-116"]}
{"ID": "DDI-DrugBank.d5.s12.p1", "TEXT1": "Many drugs, including most @DRUG$ (SSRIs, many tricyclics), @DRUG$, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme. Therefore, AUGMENTIN XR may change the efficacy of these other drugs.", "LBL": "0", "DRUGA": ["antidepressants", "group", "78-92"], "DRUGB": ["beta-blockers", "group", "120-132"]}
{"ID": "DDI-DrugBank.d5.s12.p2", "TEXT1": "Many drugs, including most SSRIs, many tricyclics, beta-blockers, and antipsychotics, are metabolized by the CYP2D6 isoenzyme. Therefore, the concomitant administration of such drugs with @DRUG$ should be avoided.", "LBL": "0", "DRUGA": ["antidepressants", "group", "78-92"], "DRUGB": ["antiarrhythmics", "drug", "135-149"]}
{"ID": "DDI-DrugBank.d5.s12.p3", "TEXT1": "Many drugs, including most @DRUG$ (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme. This means that taking them together could decrease the plasma concentrations of the drugs.", "LBL": "0", "DRUGA": ["antidepressants", "group", "78-92"], "DRUGB": ["antipsychotics", "group", "156-169"]}
{"ID": "DDI-DrugBank.d5.s12.p4", "TEXT1": "Many drugs, including most antidepressants (SSRIs, many @DRUG$), @DRUG$, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme. This means that taking them together could decrease the plasma concentrations of the drugs.", "LBL": "0", "DRUGA": ["tricyclics", "group", "107-116"], "DRUGB": ["beta-blockers", "group", "120-132"]}
{"ID": "DDI-DrugBank.d5.s12.p5", "TEXT1": "Many drugs, including most antidepressants (SSRIs, many @DRUG$), beta-blockers, @DRUG$, and antipsychotics, are metabolized by the CYP2D6 isoenzyme. Caution is advised if these drugs are used together.", "LBL": "0", "DRUGA": ["tricyclics", "group", "107-116"], "DRUGB": ["antiarrhythmics", "drug", "135-149"]}
{"ID": "DDI-DrugBank.d5.s12.p6", "TEXT1": "Many drugs, including most antidepressants (SSRIs, many @DRUG$), beta-blockers, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme. This may reduce the efficacy of these drugs when taken with AUGMENTIN XR.", "LBL": "0", "DRUGA": ["tricyclics", "group", "107-116"], "DRUGB": ["antipsychotics", "group", "156-169"]}
{"ID": "DDI-DrugBank.d5.s12.p7", "TEXT1": "Many drugs which include the majority of antidepressants (SSRIs, many tricyclics), @DRUG$, @DRUG$, and antipsychotics are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "120-132"], "DRUGB": ["antiarrhythmics", "drug", "135-149"]}
{"ID": "DDI-DrugBank.d5.s12.p8", "TEXT1": "The concomitant administration of drugs that are metabolized by the CYP2D6 isoenzyme, such as most antidepressants (SSRIs, many tricyclics), @DRUG$, antiarrhythmics, and @DRUG$, shall be avoided.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "120-132"], "DRUGB": ["antipsychotics", "group", "156-169"]}
{"ID": "DDI-DrugBank.d5.s12.p9", "TEXT1": "Some drugs (including most antidepressants, beta-blockers, and @DRUG$) are metabolized by the CYP2D6 isoenzyme. Eating foods or taking drugs that contain @DRUG$ may interfere with the absorption of these drugs.", "LBL": "0", "DRUGA": ["antiarrhythmics", "drug", "135-149"], "DRUGB": ["antipsychotics", "group", "156-169"]}
{"ID": "DDI-DrugBank.d5.s13.p0", "TEXT1": "Although @DRUG$ is not metabolized by the CYP2D6 isoenzyme, @DRUG$ and hydroxybupropion may inhibit the CYP2D6 isoenzyme in vitro.", "LBL": "0", "DRUGA": ["bupropion", "drug", "9-17"], "DRUGB": ["bupropion", "drug", "57-65"]}
{"ID": "DDI-DrugBank.d5.s13.p1", "TEXT1": "Since @DRUG$ is not metabolized by this isoenzyme, it's possible that bupropion and @DRUG$ could inhibit the CYP2D6 isoenzyme when used together.", "LBL": "0", "DRUGA": ["bupropion", "drug", "9-17"], "DRUGB": ["hydroxybupropion", "drug_n", "71-86"]}
{"ID": "DDI-DrugBank.d5.s13.p2", "TEXT1": "Although bupropion is not metabolized by the CYP2D6 isoenzyme, @DRUG$ and @DRUG$ may inhibit this enzyme in vitro.", "LBL": "0", "DRUGA": ["bupropion", "drug", "57-65"], "DRUGB": ["hydroxybupropion", "drug_n", "71-86"]}
{"ID": "DDI-DrugBank.d5.s14.p0", "TEXT1": "In a study of 15 male subjects who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of @DRUG$ given as 150 mg twice daily followed by a single dose of 50 mg @DRUG$ increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively. These finding suggest that caution should be exercised if these two drugs are used together.", "LBL": "DDI-mechanism", "DRUGA": ["bupropion", "drug", "125-133"], "DRUGB": ["desipramine", "drug", "198-208"]}
{"ID": "DDI-DrugBank.d5.s14.p1", "TEXT1": "In a study of 15 male subjects (ages 19 to 35 years), it was found that taking @DRUG$ along with desipramine caused an increase in the maximum concentration, area under the curve, and half-life of @DRUG$.", "LBL": "0", "DRUGA": ["bupropion", "drug", "125-133"], "DRUGB": ["desipramine", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s14.p2", "TEXT1": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg @DRUG$ increased the Cmax, AUC, and t1/2 of @DRUG$ by an average of approximately 2-, 5- and 2-fold, respectively. These results suggest that caution is recommended if these two drugs are used together.", "LBL": "0", "DRUGA": ["desipramine", "drug", "198-208"], "DRUGB": ["desipramine", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p0", "TEXT1": "Co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme, including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["antidepressants", "group", "112-126"]}
{"ID": "DDI-DrugBank.d5.s17.p1", "TEXT1": "Therefore, co-administration of @DRUG$ with other medications that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. To initiate this drug combination, it is recommended to start at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["nortriptyline", "drug", "135-147"]}
{"ID": "DDI-DrugBank.d5.s17.p2", "TEXT1": "Co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), may require a lower dose of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["imipramine", "drug", "150-159"]}
{"ID": "DDI-DrugBank.d5.s17.p3", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["desipramine", "drug", "162-172"]}
{"ID": "DDI-DrugBank.d5.s17.p4", "TEXT1": "Therefore, it is recommended to use caution when co-administering @DRUG$ with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). When starting co-administration of these drugs, it is recommended to begin at the lower end of the dose range for the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s17.p5", "TEXT1": "Consequently, while drugs that are processed by CYP2D6 isoenzyme are being co-administered with @DRUG$, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), one should use caution and initiate said dosages at the lower end of the recommended range.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p6", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. The dose of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p7", "TEXT1": "Therefore, it is recommended to exercise caution if @DRUG$ and @DRUG$ are used together. This is because @DRUG$ may affect the metabolism of certain drugs, including certain antidepressants, @DRUG$, beta-blockers, and Type 1C antiarrhythmics. If co-administration is necessary, it is recommended to start at the lower end of the dose range for the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p8", "TEXT1": "Coadministration of @DRUG$ with drugs that are metabolized by the CYP2D6 enzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p9", "TEXT1": "The concomitant administration of drugs that are metabolized by the CYP2D6 isoenzyme, including @DRUG$ and @DRUG$, should be approached with caution. These drugs include certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). They should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p10", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide) should be approached with caution and initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p11", "TEXT1": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p12", "TEXT1": "There is the potential for a drug interaction when @DRUG$ is taken with certain medications that are metabolized by the CYP2D6 isoenzyme. These medications include certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Therefore, it is recommended that @DRUG$ be initiated at the lower end of the dose range of the concomitant medication when taken with these drugs.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p13", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution. The dose of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p14", "TEXT1": "Therefore, @DRUG$ should be used with caution and at the lower end of the dose range when co-administered with medications that are metabolized by CYP2D6, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide).", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p15", "TEXT1": "Therefore, co-administration of @DRUG$ with certain drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics, should be done with caution, and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p16", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["nortriptyline", "drug", "135-147"]}
{"ID": "DDI-DrugBank.d5.s17.p17", "TEXT1": "The concomitant administration of bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme (such as certain @DRUG$) should be done with caution, and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["imipramine", "drug", "150-159"]}
{"ID": "DDI-DrugBank.d5.s17.p18", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. The dose of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["desipramine", "drug", "162-172"]}
{"ID": "DDI-DrugBank.d5.s17.p19", "TEXT1": "Co-administration of bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s17.p20", "TEXT1": "Given that bupropion is metabolized by the CYP2D6 isoenzyme, co-administration of bupropion with other drugs that are also metabolized by this enzyme (e.g., @DRUG$, antipsychotics, beta-blockers, and Type 1C antiarrhythmics) should be done with caution, and at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p21", "TEXT1": "The concomitant administration of drugs that are metabolized by CYP2D6, such as certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), with bupropion should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p22", "TEXT1": "The use of bupropion in combination with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. When initiating treatment with bupropion, clinicians should start at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p23", "TEXT1": "Therefore, co-administration of bupropion with drugs metabolized by the CYP2D6 isoenzyme, such as certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p24", "TEXT1": "co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p25", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide) should be approached with caution. The dose of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p26", "TEXT1": "Coadministration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p27", "TEXT1": "Therefore, it is prudent to be cautious when co-administering bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). It is recommended to initiate dosing at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p28", "TEXT1": "Due to the potential for decreased plasma concentrations, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p29", "TEXT1": "Bupropion may reduce the efficacy of certain drugs that are metabolized by the CYP2D6 enzyme, including @DRUG$, antipsychotics, beta-blockers, and Type 1C antiarrhythmics. Therefore, caution should be used when initiating treatment with bupropion at the lower end of the dose range.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p30", "TEXT1": "If you're taking bupropion, be cautious when also taking drugs that are metabolized by the CYP2D6 isoenzyme, such as certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$). It's best to start with the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p31", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["imipramine", "drug", "150-159"]}
{"ID": "DDI-DrugBank.d5.s17.p32", "TEXT1": "When taking bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, it is important to be cautious and start at a lower dose. This includes certain antidepressants (e.g., @DRUG$, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide).", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["desipramine", "drug", "162-172"]}
{"ID": "DDI-DrugBank.d5.s17.p33", "TEXT1": "Therefore, it is best to approach co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), with caution and to initiate at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s17.p34", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p35", "TEXT1": "Consequently, when administering bupropion alongside drugs that are processed by CYP2D6 isoenzyme\u2014such as particular antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide)\u2014it is important to exercise caution and begin at the lower end of the dose range for the concurrent medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p36", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p37", "TEXT1": "Some medications may interfere with the absorption of bupropion, so it's important to approach co-administration with caution. These medications include certain antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics. When starting bupropion with one of these medications, it's important to start at a lower dose.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p38", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p39", "TEXT1": "Bupropion may interact with certain medications that are metabolized by the CYP2D6 enzyme, including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Therefore, caution is advised when co-administering bupropion with these drugs, and therapy should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p40", "TEXT1": "Coadministration of bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be done with caution and at the lower end of the dose range.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p41", "TEXT1": "Therefore, caution should be used when co-administering bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, such as certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). It is recommended to initiate dosing at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p42", "TEXT1": "When using bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, caution is advised. These drugs include certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide). It is recommended to start at the lower end of the dose range when using these medications together.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p43", "TEXT1": "If @DRUG$ and @DRUG$ are used together, care should be taken. This is because bupropion is metabolized by the CYP2D6 isoenzyme, which is also responsible for metabolizing certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide). When starting treatment with both bupropion and one of these other medications, it is recommended to begin at the lower end of the dose range for the other medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p44", "TEXT1": "Therefore, when taking bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), it is important to be cautious and start at the lower end of the dose range.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p45", "TEXT1": "approach the co-administration of bupropion with caution, and initiate the dose of the concomitant medication at the lower end of the range.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["desipramine", "drug", "162-172"]}
{"ID": "DDI-DrugBank.d5.s17.p46", "TEXT1": "There is a potential for increased adverse effects when bupropion is co-administered with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Therefore, caution should be exercised when initiating bupropion therapy at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s17.p47", "TEXT1": "Therefore, it is advised to use caution when co-administering bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). It is recommended to initiate dosing at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p48", "TEXT1": "If you are taking bupropion with other drugs that are metabolized by the CYP2D6 enzyme, such as certain antidepressants (e.g. nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g. haloperidol, risperidone, thioridazine), beta-blockers (e.g. metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, flecainide), it is important to approach the situation with caution. You should initiate taking the other medication at the lower end of the dose range.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p49", "TEXT1": "Cautiousness is advised if bupropion is used concurrently with other medications that are metabolized by the CYP2D6 isoenzyme, such as certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). It is recommended to start at the lower end of the dose range when combining bupropion with any of these medications.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p50", "TEXT1": "administration of bupropion with other drugs that are metabolized by the CYP2D6 enzyme, including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p51", "TEXT1": "Therefore, it is recommended to exercise caution if bupropion and drugs that are metabolized by the CYP2D6 isoenzyme are used together, including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). doses of the concomitant medication should be initiated at the lower end of the range.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p52", "TEXT1": "Some medications may reduce the absorption of bupropion, so it's important to take them at the lower end of the dose range. This applies to certain antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p53", "TEXT1": "When taking bupropion with other medications, it is important to start at a lower dose and increase cautiously. This is because bupropion can decrease the effectiveness of certain medications that are metabolized by the CYP2D6 isoenzyme. These medications include antidepressants (e.ckd. nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide).", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p54", "TEXT1": "Co-administration of bupropion with certain drugs that are metabolized by CYP2D6 isoenzyme, including antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics, should be approached with caution and initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p55", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p56", "TEXT1": "Under certain circumstances, taking bupropion with drugs that are metabolized by the CYP2D6 enzyme could result in reduced efficacy of the medications. These drugs include certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide). When starting bupropion with any of these medications, it is important to begin at a lower dose and approach the situation with caution.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p57", "TEXT1": "Making sure to start at a lower dose, co-administration of bupropion with drugs that are metabolized by the CYP2D6 isoenzyme (including certain antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics) should be approached with caution.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p58", "TEXT1": "Therefore, it is advisable to exercise caution when co-administering bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). It is recommended to initiate treatment at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s17.p59", "TEXT1": "Bupropion may interfere with the absorption of other drugs that are metabolized by the CYP2D6 isoenzyme. Therefore, caution should be used when co-administering bupropion with other drugs, and the dose of the other drug should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p60", "TEXT1": "Co-administration of bupropion with drugs metabolized by CYP2D6 isoenzyme, including certain antidepressants (nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, @DRUG$), antipsychotics (haloperidol, risperidone, thioridazine), beta-blockers (metoprolol), and Type 1C antiarrhythmics (propafenone, flecainide), should be approached with caution. The dose of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p61", "TEXT1": "If you're taking bupropion, be cautious about taking other medications that are metabolized by the CYP2D6 enzyme. This includes certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). It's best to start at the lower end of the dose range when taking these medications together.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p62", "TEXT1": "Therefore, when taking bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme (including certain antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics), it's important to start at the lower end of the dose range for the other drug.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p63", "TEXT1": "The concurrent use of bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, such as certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be done with caution and at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p64", "TEXT1": "The concomitant use of bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, such as certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. These medications should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p65", "TEXT1": "It is therefore advised to approach co-administration of bupropion with caution, and to initiate dosing at the lower end of the range for the concomitant medication, when co-administering with drugs that are metabolized by the CYP2D6 isoenzyme. This includes certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide).", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p66", "TEXT1": "The concomitant administration of bupropion with other medications that are metabolized by the CYP2D6 isoenzyme (such as certain antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics) should be approached with caution, and the dosage of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p67", "TEXT1": "Given that bupropion is metabolized by the CYP2D6 isoenzyme, co-administration of bupropion with other drugs that are also metabolized by this enzyme (such as certain antidepressants, antipsychotics, beta-blockers, and @DRUG$) should be approached with caution. The recommended starting dose for the concomitant medication should be at the lower end of the dose range.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p68", "TEXT1": "Approaching co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme with caution is advised, including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide). This should be initiated at a lower dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p69", "TEXT1": "Therefore, caution should be used when co-administering bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$). The lower end of the dose range of the concomitant medication should be used when initiating therapy.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p70", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p71", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be cautiously approached and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p72", "TEXT1": "Because of the risk of decreased efficacy or increased toxicity, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. The dose of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p73", "TEXT1": "The concomitant administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. These medications should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p74", "TEXT1": "Bupropion may interact with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Therefore, caution is advised when co-administering these medications, and the dose of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p75", "TEXT1": "Given that bupropion is metabolized by CYP2D6, caution should be exercised when co-administering it with other drugs that are also metabolized by this isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). In these cases, it is recommended to start at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p76", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be started cautiously, and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p77", "TEXT1": "Like other drugs in its class, AUGMENTIN XR may interact with certain other medications, reducing their efficacy. Therefore, it is important to approach co-administration of bupropion with caution, starting at the lower end of the dose range for the other medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p78", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p79", "TEXT1": "Coadministration of bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution. Dosing of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p80", "TEXT1": "Therefore, it's important to be cautious when co-administering bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$). When starting bupropion with these medications, it's best to begin at the lower end of the dose range.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p81", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p82", "TEXT1": "Some drugs may interfere with the absorption of bupropion. Therefore, care should be taken when co-administering bupropion with other drugs. It is advisable to start at the lower end of the dose range when co-administering bupropion with other medications.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p83", "TEXT1": "The concomitant administration of bupropion with certain other drugs may not be recommended, as they may interact with each other. These drugs include antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Therefore, it is recommended to approach co-administration of these drugs with caution, and to start at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p84", "TEXT1": "Therefore, it is recommended to approach co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme (such as certain antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics) with caution, and to begin at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p85", "TEXT1": "As a result, caution should be used when co-administering bupropion with drugs that are metabolized by the CYP2D6 isoenzyme. This includes certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). The lower end of the dose range should be used when initiating co-administration of these medications.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p86", "TEXT1": "Therefore, it's important to approach co-administration of bupropion with caution, and to start at the lower end of the dose range for the concomitant medication, when bupropion is being used with drugs that are metabolized by the CYP2D6 isoenzyme. This includes certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide).", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p87", "TEXT1": "Therefore, it is important to use caution when co-administering bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Starting at the lower end of the dose range is recommended.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p88", "TEXT1": "Therefore, it is suggested to caution when co-administering bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), and to begin at a lower dose of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p89", "TEXT1": "When taking bupropion with other drugs, please be cautious as bupropion may impact the metabolism of these drugs. These drugs include certain antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics. If you are taking any of these medications, it is recommended to start at the lower end of the dose range.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p90", "TEXT1": "Cautiousness is recommended when using bupropion with other drugs that are metabolized by CYP2D6, such as certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$). Lower doses of the concomitant medication should be used when starting bupropion.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p91", "TEXT1": "The co-administration of bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. These medications should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p92", "TEXT1": "Therefore, concomitant administration of bupropion with drugs metabolized by the CYP2D6 isoenzyme, such as certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and initiated at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p93", "TEXT1": "Therefore, caution is advised when co-administering bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Treatment should be initiated at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p94", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p95", "TEXT1": "The concomitant administration of bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme should be done with caution, and should be initiated at the lower end of the dose range of the concomitant medication. This is because bupropion may increase the levels of these other drugs in the body. Examples of such other drugs include certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide).", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p96", "TEXT1": "Please exercise caution when co-administering bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, such as certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). In such cases, it is recommended to start at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p97", "TEXT1": "Therefore, it is recommended to exercise caution when co-administering bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide). To start, it is recommended to initiate dosing at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p98", "TEXT1": "Therefore, when taking bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, it is important to be cautious and start at a lower dose. This includes certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide).", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p99", "TEXT1": "co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants, antipsychotics, beta-blockers and Type 1C antiarrhythmics, should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p100", "TEXT1": "Approaching co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be done with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p101", "TEXT1": "The concomitant administration of bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be initiated at the lower end of the dose range and with caution.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p102", "TEXT1": "There is a potential for drug interactions when bupropion is taken with other drugs that are metabolized by the CYP2D6 enzyme, such as certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Therefore, it is important to be cautious when initiating bupropion at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p103", "TEXT1": "The co-administration of bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p104", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. The dose of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p105", "TEXT1": "Given that co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme can cause decreased plasma concentrations of bupropion, caution should be used when initiating bupropion treatment at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p106", "TEXT1": "There is a potential for interactions when co-administering bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide). Caution is advised when initiating treatment at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p107", "TEXT1": "Therefore, when bupropion is taken with other drugs that are metabolized by the CYP2D6 enzyme (including certain antidepressants, @DRUG$ drugs, beta-blockers, and Type 1C antiarrhythmics), it is important to start at the lower end of the dose range for the other drug, and to approach the situation with caution.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p108", "TEXT1": "Therefore, caution should be exercised when co-administering bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). The dose of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p109", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p110", "TEXT1": "CYP2D6 isoenzyme-metabolized drugs, such as certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), may have reduced absorption when co-administered with bupropion. Therefore, caution should be used when initiating bupropion therapy at the lower end of the dose range for these drugs.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p111", "TEXT1": "Co-administration of bupropion with drugs that are metabolized by the CYP2D6 enzyme, such as certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p112", "TEXT1": "Therefore, bupropion should be used with caution in patients taking drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide). The dose of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p113", "TEXT1": "Consequently, it is delicate to co-administer bupropion with drugs that are metabolized by CYP2D6 isoenzyme including particular antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide). The dosage of the concomitant medication should be initiated at the lower end of the dose range.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p114", "TEXT1": "Therefore, extra caution is advised when co-administering bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$). It is recommended to start at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p115", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p116", "TEXT1": "CYP2D6 isoenzyme-metabolized drugs include certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Therefore, co-administration of bupropion with any of these medications should be done with caution and at the lower end of the dose range.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p117", "TEXT1": "Co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution, and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p118", "TEXT1": "Therefore, cautiousness is advised when co-administering bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, such as certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide). The dose of the concomitant medication should be initiated at the lower end of the range.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p119", "TEXT1": "Therefore, it's important to exercise caution when co-administering bupropion with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide). In these cases, it's best to start at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p120", "TEXT1": "Approach co-administration of bupropion with caution when also taking other medications that are processed by CYP2D6 isoenzyme. These include certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$). Start at the lower end of the dose range when initiating bupropion with these other medications.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p121", "TEXT1": "Should you take @DRUG$ and @DRUG$ together, use caution and start at a lower dose of the concomitant medication.", "LBL": "0", "DRUGA": ["thioridazine", "drug", "260-271"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p122", "TEXT1": "Therefore, when using bupropion in conjunction with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), it is recommended to use caution and initiate dosing at the lower end of the dose range.", "LBL": "0", "DRUGA": ["thioridazine", "drug", "260-271"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p123", "TEXT1": "Bupropion may interact with other medications that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide). Therefore, caution should be used when co-administering bupropion with these medications, and therapy should be initiated at the lower end of the dose range for the concomitant medication.", "LBL": "0", "DRUGA": ["thioridazine", "drug", "260-271"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p124", "TEXT1": "Consequently, anyone taking bupropion should use caution when combining it with other drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide). It is generally recommended to start at the lower end of the dose range when combining bupropion with any of these other medications.", "LBL": "0", "DRUGA": ["thioridazine", "drug", "260-271"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p125", "TEXT1": "Given that bupropion is metabolized by the CYP2D6 isoenzyme, caution is advised when co-administering bupropion with other drugs that are metabolized by this enzyme, such as certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$). When initiating treatment with bupropion in such cases, the lower end of the dose range should be used.", "LBL": "0", "DRUGA": ["thioridazine", "drug", "260-271"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p126", "TEXT1": "Therefore, when taking bupropion with other medications that are metabolized by the CYP2D6 isoenzyme (such as certain antidepressants, antipsychotics, and @DRUG$), it's best to start at the lower end of the dose range for the other medication.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "275-287"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p127", "TEXT1": "The concomitant administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be done with caution and the dose of the concomitant medication should be initiated at the lower end of the range.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "275-287"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p128", "TEXT1": "Therefore, it is recommended to exercise caution if bupropion and drugs that are metabolized by the CYP2D6 isoenzyme are used together. This includes certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide). These medications should be initiated at the lower end of the dose range when used in conjunction with bupropion.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "275-287"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p129", "TEXT1": "Bupropion should be co-administered with caution and at a lower dose when taken with drugs that are metabolized by the CYP2D6 isoenzyme. These drugs include certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$).", "LBL": "0", "DRUGA": ["beta-blockers", "group", "275-287"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p130", "TEXT1": "You should be cautious when co-administering bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and @DRUG$ (e.g., propafenone, flecainide). You should start at the lower end of the dose range when initiating co-administration.", "LBL": "0", "DRUGA": ["metoprolol", "drug", "296-305"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p131", "TEXT1": "Co-administration of bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution, and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["metoprolol", "drug", "296-305"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p132", "TEXT1": "CYP2D6 isoenzyme-metabolized drugs, such as certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), require cautious co-administration with bupropion, preferably at the lower end of the dose range.", "LBL": "0", "DRUGA": ["metoprolol", "drug", "296-305"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p133", "TEXT1": "Some medications can interfere with the absorption of bupropion. Therefore, it is important to approach co-administration of bupropion with caution, and to start at the lower end of the dose range when combining with other medications.", "LBL": "0", "DRUGA": ["Type 1C antiarrhythmics", "group", "313-335"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p134", "TEXT1": "Co-administration of bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, @DRUG$), should be done with caution and should start at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["Type 1C antiarrhythmics", "group", "313-335"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p135", "TEXT1": "Coadministration of bupropion with drugs that are metabolized by the CYP2D6 isoenzyme, including certain antidepressants (eg, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (eg, haloperidol, risperidone, thioridazine), beta-blockers (eg, metoprolol), and Type 1C antiarrhythmics (eg, @DRUG$, @DRUG$), should be approached with caution and should be initiated at lower doses than usual for the concomitant medication.", "LBL": "0", "DRUGA": ["propafenone", "drug", "344-354"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s19.p0", "TEXT1": "Although @DRUG$ is not typically considered dangerous, studies in animals have shown that its acute toxicity is enhanced by the MAO inhibitor phenelzine. This means that caution should be exercised if @DRUG$ is taken in combination with this type of medication.", "LBL": "0", "DRUGA": ["MAO Inhibitors", "group", "0-13"], "DRUGB": ["bupropion", "drug", "74-82"]}
{"ID": "DDI-DrugBank.d5.s19.p1", "TEXT1": "Bupropion: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the drug phenelzine.", "LBL": "0", "DRUGA": ["MAO Inhibitors", "group", "0-13"], "DRUGB": ["MAO inhibitor", "group", "103-115"]}
{"ID": "DDI-DrugBank.d5.s19.p2", "TEXT1": "@DRUG$: Animal studies show that @DRUG$ increases the acute toxicity of bupropion.", "LBL": "0", "DRUGA": ["MAO Inhibitors", "group", "0-13"], "DRUGB": ["phenelzine", "drug", "117-126"]}
{"ID": "DDI-DrugBank.d5.s19.p3", "TEXT1": "MAO Inhibitors: Studies in animals show that @DRUG$ is more toxic when taken with phenelzine.", "LBL": "0", "DRUGA": ["bupropion", "drug", "74-82"], "DRUGB": ["MAO inhibitor", "group", "103-115"]}
{"ID": "DDI-DrugBank.d5.s19.p4", "TEXT1": "Animal studies have shown that @DRUG$ is more toxic when used with an MAO inhibitor like @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["bupropion", "drug", "74-82"], "DRUGB": ["phenelzine", "drug", "117-126"]}
{"ID": "DDI-DrugBank.d5.s19.p5", "TEXT1": "Some studies in animals have found that the acute toxicity of bupropion may be increased when used in combination with @DRUG$ and @DRUG$. Therefore, caution is advised if you are taking bupropion along with these other medications.", "LBL": "0", "DRUGA": ["MAO inhibitor", "group", "103-115"], "DRUGB": ["phenelzine", "drug", "117-126"]}
{"ID": "DDI-DrugBank.d5.s20.p0", "TEXT1": "Clinical data suggests that patients taking bupropion and either levodopa or amantadine may experience more adverse effects.", "LBL": "0", "DRUGA": ["Levodopa", "drug", "0-7"], "DRUGB": ["Amantadine", "drug", "13-22"]}
{"ID": "DDI-DrugBank.d5.s20.p1", "TEXT1": "Data from clinical studies suggests that patients who take @DRUG$ along with either levodopa or amantadine may experience more adverse effects.", "LBL": "0", "DRUGA": ["Levodopa", "drug", "0-7"], "DRUGB": ["bupropion", "drug", "119-127"]}
{"ID": "DDI-DrugBank.d5.s20.p2", "TEXT1": "There is limited clinical data to suggest that patients who take bupropion with either @DRUG$ or amantadine may have a higher incidence of adverse experiences.", "LBL": "0", "DRUGA": ["Levodopa", "drug", "0-7"], "DRUGB": ["levodopa", "drug", "154-161"]}
{"ID": "DDI-DrugBank.d5.s20.p3", "TEXT1": "@DRUG$ and Amantadine: Limited clinical data suggest that patients receiving bupropion concurrently with either levodopa or @DRUG$ may experience more adverse effects.", "LBL": "0", "DRUGA": ["Levodopa", "drug", "0-7"], "DRUGB": ["amantadine", "drug", "166-175"]}
{"ID": "DDI-DrugBank.d5.s20.p4", "TEXT1": "There is limited clinical data available that suggests a higher incidence of adverse experiences in patients receiving @DRUG$ concurrently with either levodopa or amantadine.", "LBL": "0", "DRUGA": ["Amantadine", "drug", "13-22"], "DRUGB": ["bupropion", "drug", "119-127"]}
{"ID": "DDI-DrugBank.d5.s20.p5", "TEXT1": "There is limited clinical data available on the use of bupropion with levodopa or amantadine. Some patients may experience more adverse effects when taking these drugs together.", "LBL": "0", "DRUGA": ["Amantadine", "drug", "13-22"], "DRUGB": ["levodopa", "drug", "154-161"]}
{"ID": "DDI-DrugBank.d5.s20.p6", "TEXT1": "Limited clinical data exists to suggest that patients receiving bupropion concurrently with either levodopa or @DRUG$ may be more likely to experience adverse experiences.", "LBL": "0", "DRUGA": ["Amantadine", "drug", "13-22"], "DRUGB": ["amantadine", "drug", "166-175"]}
{"ID": "DDI-DrugBank.d5.s20.p7", "TEXT1": "There is limited clinical data available on the potential adverse effects of taking @DRUG$ concurrently with either @DRUG$ or amantadine.", "LBL": "DDI-effect", "DRUGA": ["bupropion", "drug", "119-127"], "DRUGB": ["levodopa", "drug", "154-161"]}
{"ID": "DDI-DrugBank.d5.s20.p8", "TEXT1": "There is limited clinical data to suggest that patients receiving @DRUG$ concurrently with either levodopa or @DRUG$ may experience more adverse effects.", "LBL": "DDI-effect", "DRUGA": ["bupropion", "drug", "119-127"], "DRUGB": ["amantadine", "drug", "166-175"]}
{"ID": "DDI-DrugBank.d5.s20.p9", "TEXT1": "There is limited clinical data available on the use of bupropion in conjunction with either @DRUG$ or @DRUG$. However, some patients may experience more adverse reactions when taking these medications together.", "LBL": "0", "DRUGA": ["levodopa", "drug", "154-161"], "DRUGB": ["amantadine", "drug", "166-175"]}
{"ID": "DDI-DrugBank.d5.s21.p0", "TEXT1": "Caution should be used when administering @DRUG$ Tablets to patients who are also taking either @DRUG$ or amantadine, using small initial doses and small gradual dose increases.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "18-27"], "DRUGB": ["levodopa", "drug", "66-73"]}
{"ID": "DDI-DrugBank.d5.s21.p1", "TEXT1": "Administration of @DRUG$ Tablets to patients receiving either levodopa or @DRUG$ concurrently can be undertaken with caution, using small initial doses and small gradual dose increases.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "18-27"], "DRUGB": ["amantadine", "drug", "78-87"]}
{"ID": "DDI-DrugBank.d5.s21.p2", "TEXT1": "Administration of WELLBUTRIN Tablets to patients receiving either @DRUG$ or @DRUG$ concurrently requires caution, using small initial doses and small gradual dose increases.", "LBL": "0", "DRUGA": ["levodopa", "drug", "66-73"], "DRUGB": ["amantadine", "drug", "78-87"]}
{"ID": "DDI-DrugBank.d5.s22.p0", "TEXT1": "Concurrent administration of @DRUG$ and agents that lower seizure threshold, such as other antidepressants, theophylline, and systemic steroids, should be undertaken only with extreme caution.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "65-74"], "DRUGB": ["antipsychotics", "group", "94-107"]}
{"ID": "DDI-DrugBank.d5.s22.p1", "TEXT1": "Concurrent administration of @DRUG$ and agents that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "65-74"], "DRUGB": ["antidepressants", "group", "116-130"]}
{"ID": "DDI-DrugBank.d5.s22.p2", "TEXT1": "Concurrent administration of @DRUG$ and agents that lower seizure threshold should be done with caution.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "65-74"], "DRUGB": ["theophylline", "drug", "133-144"]}
{"ID": "DDI-DrugBank.d5.s22.p3", "TEXT1": "The concurrent administration of @DRUG$ and agents that lower seizure threshold (e.g., antipsychotics, other antidepressants, theophylline, systemic @DRUG$, etc.) should be undertaken with caution.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "65-74"], "DRUGB": ["steroids", "group", "156-163"]}
{"ID": "DDI-DrugBank.d5.s22.p4", "TEXT1": "Concurrent administration of WELLBUTRIN and agents (e.g., @DRUG$, other @DRUG$, theophylline, systemic steroids, etc.) that lower seizure threshold may require extra caution.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "94-107"], "DRUGB": ["antidepressants", "group", "116-130"]}
{"ID": "DDI-DrugBank.d5.s22.p5", "TEXT1": "Concurrent administration of WELLBUTRIN and agents that lower seizure threshold should be undertaken only with extreme caution. These agents include @DRUG$, other antidepressants, @DRUG$, and systemic steroids.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "94-107"], "DRUGB": ["theophylline", "drug", "133-144"]}
{"ID": "DDI-DrugBank.d5.s22.p6", "TEXT1": "Concurrent administration of WELLBUTRIN and agents that lower seizure threshold (e.g., @DRUG$, other antidepressants, theophylline, systemic @DRUG$, etc.) should be undertaken only with extreme caution.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "94-107"], "DRUGB": ["steroids", "group", "156-163"]}
{"ID": "DDI-DrugBank.d5.s22.p7", "TEXT1": "Concurrent administration of WELLBUTRIN and agents that lower seizure threshold (e.g., antipsychotics, other @DRUG$, @DRUG$, systemic steroids, etc.) should be undertaken with caution.", "LBL": "0", "DRUGA": ["antidepressants", "group", "116-130"], "DRUGB": ["theophylline", "drug", "133-144"]}
{"ID": "DDI-DrugBank.d5.s22.p8", "TEXT1": "Concurrent administration of WELLBUTRIN with agents that lower seizure threshold (e.g., antipsychotics, other @DRUG$, theophylline, systemic @DRUG$, etc.) should be undertaken only with caution.", "LBL": "0", "DRUGA": ["antidepressants", "group", "116-130"], "DRUGB": ["steroids", "group", "156-163"]}
{"ID": "DDI-DrugBank.d5.s22.p9", "TEXT1": "Please use caution when administering WELLBUTRIN alongside other agents that have the potential to lower seizure threshold (e.g., antipsychotics, other antidepressants, @DRUG$, systemic @DRUG$, etc.).", "LBL": "0", "DRUGA": ["theophylline", "drug", "133-144"], "DRUGB": ["steroids", "group", "156-163"]}
{"ID": "DDI-DrugBank.d5.s25.p0", "TEXT1": "It is best to avoid drinking alcohol while taking WELLBUTRIN, as it may increase the risk of adverse neuropsychiatric events or reduced tolerance to the medication.", "LBL": "0", "DRUGA": ["Alcohol", "drug", "0-6"], "DRUGB": ["alcohol", "drug", "114-120"]}
{"ID": "DDI-DrugBank.d5.s25.p1", "TEXT1": "There have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking @DRUG$ during treatment with WELLBUTRIN.", "LBL": "0", "DRUGA": ["Alcohol", "drug", "0-6"], "DRUGB": ["alcohol", "drug", "162-168"]}
{"ID": "DDI-DrugBank.d5.s25.p2", "TEXT1": "There have been a few reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with @DRUG$.", "LBL": "0", "DRUGA": ["Alcohol", "drug", "0-6"], "DRUGB": ["WELLBUTRIN", "brand", "192-201"]}
{"ID": "DDI-DrugBank.d5.s25.p3", "TEXT1": "There have been rare reports of adverse neuropsychiatric events or reduced @DRUG$ tolerance in patients who were drinking @DRUG$ during treatment with WELLBUTRIN.", "LBL": "0", "DRUGA": ["alcohol", "drug", "114-120"], "DRUGB": ["alcohol", "drug", "162-168"]}
{"ID": "DDI-DrugBank.d5.s25.p4", "TEXT1": "In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced @DRUG$ tolerance in patients who were drinking alcohol during treatment with @DRUG$.", "LBL": "0", "DRUGA": ["alcohol", "drug", "114-120"], "DRUGB": ["WELLBUTRIN", "brand", "192-201"]}
{"ID": "DDI-DrugBank.d5.s25.p5", "TEXT1": "There have been rare reports in post-marketing experience of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking @DRUG$ during treatment with @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["alcohol", "drug", "162-168"], "DRUGB": ["WELLBUTRIN", "brand", "192-201"]}
{"ID": "DDI-DrugBank.d5.s26.p0", "TEXT1": "Patients taking @DRUG$ should avoid consuming @DRUG$, as it may increase the risk of side effects (see also contraindications).", "LBL": "DDI-advise", "DRUGA": ["alcohol", "drug", "19-25"], "DRUGB": ["WELLBUTRIN", "brand", "49-58"]}
{"ID": "DDI-DrugBank.d297.s1.p0", "TEXT1": "Population pharmacokinetic analyses have revealed that @DRUG$, @DRUG$, corticosteroids, and TNF blocking agents do not appear to influence abatacept clearance.", "LBL": "0", "DRUGA": ["MTX", "drug", "50-52"], "DRUGB": ["NSAIDs", "group", "55-60"]}
{"ID": "DDI-DrugBank.d297.s1.p1", "TEXT1": "The population pharmacokinetic analyses showed that abatacept clearance was not affected by @DRUG$, NSAIDs, @DRUG$, or TNF blocking agents.", "LBL": "0", "DRUGA": ["MTX", "drug", "50-52"], "DRUGB": ["corticosteroids", "group", "63-77"]}
{"ID": "DDI-DrugBank.d297.s1.p2", "TEXT1": "Population pharmacokinetic analyses revealed that abatacept clearance was not influenced by @DRUG$, NSAIDs, or corticosteroids.", "LBL": "0", "DRUGA": ["MTX", "drug", "50-52"], "DRUGB": ["TNF blocking agents", "group", "84-102"]}
{"ID": "DDI-DrugBank.d297.s1.p3", "TEXT1": "Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, corticosteroids, and TNF blocking agents did not have a significant impact on @DRUG$ clearance.", "LBL": "0", "DRUGA": ["MTX", "drug", "50-52"], "DRUGB": ["abatacept", "drug", "122-130"]}
{"ID": "DDI-DrugBank.d297.s1.p4", "TEXT1": "Population pharmacokinetic analyses revealed that MTX, @DRUG$, @DRUG$, and TNF blocking agents did not significantly influence abatacept clearance.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "55-60"], "DRUGB": ["corticosteroids", "group", "63-77"]}
{"ID": "DDI-DrugBank.d297.s1.p5", "TEXT1": "Population pharmacokinetic analyses revealed that MTX, @DRUG$, corticosteroids, and @DRUG$ did not have a significant influence on abatacept clearance.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "55-60"], "DRUGB": ["TNF blocking agents", "group", "84-102"]}
{"ID": "DDI-DrugBank.d297.s1.p6", "TEXT1": "Population pharmacokinetic analyses showed that MTX, @DRUG$, corticosteroids, and TNF blocking agents had no effect on @DRUG$ clearance.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "55-60"], "DRUGB": ["abatacept", "drug", "122-130"]}
{"ID": "DDI-DrugBank.d297.s1.p7", "TEXT1": "Population pharmacokinetic analyses revealed that MTX, NSAIDs, @DRUG$, and @DRUG$ had no influence on abatacept clearance.", "LBL": "0", "DRUGA": ["corticosteroids", "group", "63-77"], "DRUGB": ["TNF blocking agents", "group", "84-102"]}
{"ID": "DDI-DrugBank.d297.s1.p8", "TEXT1": "Analyses revealed that MTX, NSAIDs, @DRUG$, and TNF blocking agents did not have a significant influence on @DRUG$ clearance.", "LBL": "0", "DRUGA": ["corticosteroids", "group", "63-77"], "DRUGB": ["abatacept", "drug", "122-130"]}
{"ID": "DDI-DrugBank.d297.s1.p9", "TEXT1": "Initial analyses suggested that MTX, NSAIDs, corticosteroids, and @DRUG$ might impact @DRUG$ clearance. However, further review showed that this was not the case.", "LBL": "0", "DRUGA": ["TNF blocking agents", "group", "84-102"], "DRUGB": ["abatacept", "drug", "122-130"]}
{"ID": "DDI-DrugBank.d297.s2.p0", "TEXT1": "In most cases, patients in RA clinical studies were given one or more of the following concomitant medications along with @DRUG$: @DRUG$, NSAIDs, corticosteroids, TNF blockers, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["MTX", "drug", "124-126"]}
{"ID": "DDI-DrugBank.d297.s2.p1", "TEXT1": "The great majority of patients in RA clinical studies received at least one of the following concomitant medications with @DRUG$: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["NSAIDs", "group", "129-134"]}
{"ID": "DDI-DrugBank.d297.s2.p2", "TEXT1": "Most patients in RA clinical studies were treated with one or more of the following medications along with @DRUG$: MTX, NSAIDs, @DRUG$, TNF blockers, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["corticosteroids", "group", "137-151"]}
{"ID": "DDI-DrugBank.d297.s2.p3", "TEXT1": "Most patients in RA clinical studies were taking one or more of the following medications along with @DRUG$: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["TNF blocking agents", "group", "154-172"]}
{"ID": "DDI-DrugBank.d297.s2.p4", "TEXT1": "Most patients in RA clinical trials received one or more of the following medications along with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["azathioprine", "drug", "175-186"]}
{"ID": "DDI-DrugBank.d297.s2.p5", "TEXT1": "In most RA clinical studies, patients were given @DRUG$ along with one or more of the following other medications: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["chloroquine", "drug", "189-199"]}
{"ID": "DDI-DrugBank.d297.s2.p6", "TEXT1": "The vast majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["gold", "drug", "202-205"]}
{"ID": "DDI-DrugBank.d297.s2.p7", "TEXT1": "Many patients in RA clinical studies were also taking one or more of the following medications along with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["hydroxychloroquine", "drug", "208-225"]}
{"ID": "DDI-DrugBank.d297.s2.p8", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["leflunomide", "drug", "228-238"]}
{"ID": "DDI-DrugBank.d297.s2.p9", "TEXT1": "Most patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["sulfasalazine", "drug", "241-253"]}
{"ID": "DDI-DrugBank.d297.s2.p10", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["anakinra", "drug", "260-267"]}
{"ID": "DDI-DrugBank.d297.s2.p11", "TEXT1": "Most patients in RA clinical studies were given one or more of the following concomitant medications along with ORENCIA: @DRUG$, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["NSAIDs", "group", "129-134"]}
{"ID": "DDI-DrugBank.d297.s2.p12", "TEXT1": "Many patients in RA clinical studies received ORENCIA along with other medications, such as @DRUG$, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, or anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["corticosteroids", "group", "137-151"]}
{"ID": "DDI-DrugBank.d297.s2.p13", "TEXT1": "Most patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["TNF blocking agents", "group", "154-172"]}
{"ID": "DDI-DrugBank.d297.s2.p14", "TEXT1": "Most patients in RA clinical studies were treated with one or more of the following concomitant medications along with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["azathioprine", "drug", "175-186"]}
{"ID": "DDI-DrugBank.d297.s2.p15", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["chloroquine", "drug", "189-199"]}
{"ID": "DDI-DrugBank.d297.s2.p16", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["gold", "drug", "202-205"]}
{"ID": "DDI-DrugBank.d297.s2.p17", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["hydroxychloroquine", "drug", "208-225"]}
{"ID": "DDI-DrugBank.d297.s2.p18", "TEXT1": "Many patients in RA clinical studies received ORENCIA along with other drugs, such as @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["leflunomide", "drug", "228-238"]}
{"ID": "DDI-DrugBank.d297.s2.p19", "TEXT1": "Most patients in RA clinical studies took ORENCIA with one or more of the following other medications: @DRUG$, NSAIDs, corticosteroids, TNF blockers, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["sulfasalazine", "drug", "241-253"]}
{"ID": "DDI-DrugBank.d297.s2.p20", "TEXT1": "Most patients in RA clinical studies were taking one or more of the following concomitant medications along with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blockers, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["anakinra", "drug", "260-267"]}
{"ID": "DDI-DrugBank.d297.s2.p21", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra. These medications may help to control the condition.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["corticosteroids", "group", "137-151"]}
{"ID": "DDI-DrugBank.d297.s2.p22", "TEXT1": "Most patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["TNF blocking agents", "group", "154-172"]}
{"ID": "DDI-DrugBank.d297.s2.p23", "TEXT1": "In RA clinical studies, most patients received one or more of the following concomitant medications along with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["azathioprine", "drug", "175-186"]}
{"ID": "DDI-DrugBank.d297.s2.p24", "TEXT1": "Most patients in RA clinical studies were taking one or more of the following medications along with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["chloroquine", "drug", "189-199"]}
{"ID": "DDI-DrugBank.d297.s2.p25", "TEXT1": "The great majority of patients in RA clinical studies received at least one of the following concomitant medications along with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["gold", "drug", "202-205"]}
